Document:

EX-10.30

 EXHIBIT 10.30 
  

 
 Execution Version 

Consolidated Shareholders’ Agreement 2014 

Pieris AG, Freising, Germany 

dated October 10, 2014 

by and among 
  

	1.	Pieris AG, whose principal place of business is at Lise-Meitner-Straße 30, 85354 Freising, Germany (the “Company”), represented by its Management Board, consisting of Stephen Yoder, and its
Supervisory Board, being represented by its chairman, Dr. Hans A. Küpper; 

  

	2.	The persons listed in Exhibit A who are the holders of common shares of the Company (“Holders of Common Shares”); 

 

	3.	The persons listed in Exhibit A who are the holders of preferred shares series A of the Company (“Holders of Preferred Shares Series A”); 

 

	4.	The persons listed in Exhibit A who are the holders of preferred shares series A-1 of the Company (“Holders of Preferred Shares Series A-1”); 

 

	5.	The persons listed in Exhibit A who are the holders of preferred shares series B of the Company (“Holders of Preferred Shares Series B”); 

 

	6.	The persons listed in Exhibit A who are the (future) holders of preferred shares series C of the Company (“Holders of Preferred Shares Series C”); 

and 
  

	7.	The persons listed in Exhibit A who are indirect shareholders of the Company (“Indirect Shareholders”). 

The Holders of Common Shares, of Preferred Shares Series A, of Preferred Shares Series A-1, of Preferred Shares Series B, and of Preferred Shares Series C
shall jointly be referred to as the “Shareholders”. The Holders of Preferred Shares Series A, of Preferred Shares Series A-1, of Preferred Shares Series B and of Preferred Shares Series C shall jointly be referred to as the
“Preferred Shareholders”. The Shareholders, the Indirect Shareholders and the Company shall jointly be referred to as the “Parties”. 

 Preamble 
  

	A.	The Shareholders are the current and future shareholders of the Company, which is registered in the commercial register of the local court of Munich (the “Commercial Register”) under no. HRB
133 223. The object of the Company is the biotechnological research and development and the distribution of applications of the research results. 

  

	B.	The Company seeks further growth financing as a series C round of financing in the total amount of approx. EUR 5,000,000 in new money (equaling approx. USD 6,660,000; not taking into account the Convertible
Loans). Therefore, the Shareholders and the Company have entered into a separate investment agreement of even date (the “Investment Agreement”), of which this consolidated shareholders’ agreement 2014 (“this
Agreement” or “CSA 2014”) shall form an integral part. Capitalized terms used but not defined herein shall have the same meaning as given to them in the Investment Agreement. 

 

	C.	It is the common intention of the Shareholders that the shares of the Company are listed on a stock exchange or the Company is sold to a third party in due course. 

NOW, THEREFORE, in order to lay down the principles of the legal relationship between all Shareholders as current and future shareholders of the Company, the
Parties hereby enter into the following CSA 2014: 
 Sec. 1 

Anti-Dilution Protection / Waiver of Subscription Rights 
  

	1.	If after the increase of the share capital of the Company pursuant to Sec. 1 of the Investment Agreement, a further increase or further increases of the share capital of the Company take(s) place including, but not
limited to, an increase of the share capital utilizing authorized capital or conditional capital (“Dilutive Issue”) at a total price per share (issue price plus any contributions to the capital reserves of the Company pursuant to
§ 272 para. 2 HGB) that is less than EUR 6.04 (equaling USD 8.09) (“Original Issue Price Series C”), each Holder of Preferred Shares Series C, acting individually, is irrevocably entitled (but not obligated)
to a weighted-average anti-dilution protection by subscribing and being issued that number of additional Preferred Shares Series C at par value without premium or other contributions into the capital reserves of the Company as if such Holder of
Preferred Shares Series C had subscribed his Preferred Shares Series C according to the following formula: 

“Revised Subscription Price Series C” = 

(Outstanding shares before the Dilutive Issue x Original Issue Price Series C) + amount raised in the Dilutive Issue 

 
  

Outstanding shares after the Dilutive Issue 

(without Anti-Dilution Shares Series C and excluding any options for, or other securities convertible into, shares in the Company) 

  
 - 2 / 42 - 

 The difference between the Original Issue Price Series C and the Revised Subscription Price
Series C calculated accordingly shall be multiplied by the total number of Preferred Shares Series C held by the concerned Holder of Preferred Shares Series C and divided by the result of the Revised Subscription Price Series C minus the portion of
the Company’s share capital attributable to one share (anteiliger Betrag des Grundkapitals) (“Par Value”). 

The result then corresponds to the total number of Preferred Shares Series C which the Holders of Preferred Shares Series C may subscribe at
Par Value without premium or other contributions into the capital reserves of the Company by virtue of this anti-dilution protection (“Anti-Dilution Shares Series C”), whereby the Anti-Dilution Shares Series C shall be allocated to
the Holders of Preferred Shares Series C on a pro rata basis with regard to their shareholding of Preferred Shares Series C before the Dilutive Issue. 

Example: 
 Revised
Subscription Price Series C = 
 (Outstanding shares before the Dilutive Issue x EUR 6.04) + amount raised in the Dilutive Issue

  
  

Outstanding shares after the Dilutive Issue 

(without Anti-Dilution Shares Series C and excluding any options for, or other securities convertible into, shares in the Company) 

The difference between EUR 6.04 and the Revised Subscription Price Series C calculated accordingly shall be multiplied by the total
number of Preferred Shares Series C and divided by the result of the Revised Subscription Price Series C minus the Par Value of EUR 1.00 which equals the total number of Anti-Dilution Shares Series C which the Holders of Preferred Shares
Series C may subscribe at EUR 1.00 and pro rata according to their shareholding of Preferred Shares Series C. 

  
 - 3 / 42 - 

 With respect to the Preferred Shares Series C resulting from the conversion of the Convertible
Loans in accordance with the provisions of the Investment Agreement (the “Conversion Shares”), the above provisions shall apply separately and mutatis mutandis; provided, however, that the Original Issue Price Series C shall
be reduced to reflect the discount as provided in the Loan Agreements applied when calculating the number of Conversion Shares, and the Revised Subscription Price Series C shall likewise be calculated pursuant to the above formula but including such
reduced Original Issue Price Series C. 
  

	2.	The Holders of Preferred Shares Series C shall receive the Anti-Dilution Shares Series C in conjunction with the capital increase which led to the Dilutive Issue. For this purpose all Shareholders shall be obliged to
pass the legally required shareholders’ resolutions and to waive their statutory subscription rights to the extent necessary. 

  

	3.	The Original Issue Price Series C shall be subject to adjustments for stock splits, reverse stock splits, stock dividends and the like. 

 

	4.	In the event of more than one Dilutive Issue, the rights under this Sec. 1 may be exercised with respect to each Dilutive Issue. In case of the granting of Anti-Dilution Shares Series C the Original Issue Price
Series C shall be adjusted accordingly. 

  

	5.	 Para. 1 and 2 shall not apply with regard to (i) the securities issued upon conversion of the Preferred Shares; (ii) securities issued to
board members and employees of the Company or of affiliates (verbundene Unternehmen) within the meaning of § 15 German Stock Corporation Act (AktG) pursuant to the terms and conditions approved by the Supervisory Board, including
the member nominated pursuant to Sec. 16 para. 2 a below; (iii) securities issued as a dividend or distribution with respect to the Preferred Shares; (iv) securities issued in connection with equipment leasing, real estate,
bank financing or similar transactions approved by the Supervisory Board, including the member nominated pursuant to Sec. 16 para. 2 a below; (v) securities issued in an IPO as defined in Sec. 10 para. 6 below;
(vi) securities issued pursuant to the acquisition by the Company of another corporation or entity by consolidation, corporate reorganizations, or merger, or purchase of all or substantially all of the assets of such corporation or entity as
approved by the Supervisory Board, including the member 

  
 - 4 / 42 - 

	 	
nominated pursuant to Sec. 16 para. 2 a below; (vii) securities issued by reason of a dividend or other distribution on shares of Common Stock; (viii) any securities
issued in the course of a Compensatory Share Capital Increase pursuant to Sec. 4 para. 3 of the Investment Agreement, and (ix) any securities issued or issuable upon conversion, exercise or exchange of any other securities that are covered by
(i) - (viii). 

  

	6.	All shares in the Company shall be subject to adjustments for stock splits, reverse stock splits, stock dividends and the like. 

Sec. 2 
 Notification

  

	1.	A Shareholder intending to transfer its present or future shareholding in the Company, or a portion thereof, with or without consideration (“Offeror”) shall notify the chairman of the Company’s
Supervisory Board of such intent in writing. 

  

	2.	Such notification shall contain the following details to be provided by the Offeror: 

  

	 	a.	Name / firm and address / registered office of the Offeror; 

  

	 	b.	Name / firm and address / registered office of the potential acquirer; 

  

	 	c.	Purchase price or other consideration, as the case may be, for the intended transfer; 

  

	 	d.	Due date for payment of the purchase price or other consideration, as the case may be; 

  

	 	e.	Amount, type and series of shares intended to be transferred; 

  

	 	f.	Representations and warranties given or declared by the Offeror, as the case may be. 

 Sec. 3

 Offer to the Holders of Rights of First Refusal 
  

	1.	An Offeror intending to transfer its current or future shareholding in the Company for consideration (sale/exchange/contribution to the capital in return for shareholder rights, etc.) shall, along with a notification
pursuant to Sec. 2 hereof, offer such shares for sale to all other Shareholders. 

  
 - 5 / 42 - 

	2.	The offer is to be submitted to the Company, addressed to the chairman of the Supervisory Board. The notice shall constitute an offer vis-à-vis the Shareholders other than the Offeror and other than Shareholders
being subject to Sec. 4 para. 2 sentence 2 of this Agreement (the “First Right Holders”). The terms of the offer are to fully correspond with the terms of the offer for sale made to the potential acquirer. In the event
that consideration other than in cash is provided for, the Offeror shall state the equivalent monetary value of such consideration for the purposes of submitting the offer to the First Right Holders. The value of non-monetary consideration shall be
determined in accordance with the respective consideration’s fair market value. In the event of doubt as to the accuracy of such valuation, the Supervisory Board, by way of a 75 % majority resolution, shall be obliged to instruct an
independent expert (e.g. an auditor) to submit a report and make a determination on the fair market value of such consideration. The costs incurred as a result of instructing such expert are to be borne by the Offeror. The results of such opinion
shall be conclusive with respect to the fair market value of consideration payable for the offer for sale submitted. 

 Sec.
4 
 Exercise of Rights of First Refusal 
  

	1.	Upon receipt of the notification of the intent to transfer shares pursuant to Sec. 2, the Company, through the chairman of its Supervisory Board, shall immediately notify all other Shareholders of the contents of
the said notification and the offer contained therein and shall forward such offer to the other Shareholders in accordance with Sec. 3. The chairman of the Supervisory Board shall notify the other Shareholders of such offer by way of registered
mail. 

  

	2.	The First Right Holders are entitled to accept the offer submitted by the Offeror pursuant to Sec. 3 in accordance with the ratio their respective shareholdings in the Company bear to each other. As long as the
Offeror has not transferred the shares in respect of which it made a notification of offer pursuant to Sec. 2, and the period of two months pursuant to Sec. 7 para. 2 has not expired, such Offeror shall not be entitled to a right of first
refusal if another Shareholder submits a notification of offer pursuant to Sec. 2 prior to the expiry of the period of two months pursuant to Sec. 7 para. 2 applicable in respect of the Offeror. 

  
 - 6 / 42 - 

	3.	The First Right Holders are entitled to declare their acceptance of the offer pursuant to Sec. 3 within one month after receipt of the notification and submission of the offer pursuant to para. 1 in writing
vis-à-vis the chairman of the Supervisory Board or to exercise their tag-along right, if any, pursuant to Sec. 8 by way of written declaration vis-à-vis the chairman of the Supervisory Board within the period of notice stated. In
this declaration vis-à-vis the chairman, the First Right Holders can also declare that they accept the offer in the first line and exercise their tag-along right, if their acceptance is regarded as ineffective pursuant to Sec. 7 para. 2.
The date the respective notice is received by the chairman of the Supervisory Board shall be conclusive. 

  

	4.	Upon the notice of acceptance pursuant to para. 3 being received by the chairman of the Supervisory Board, a sale and purchase agreement between the Offeror and the respective accepting First Right Holders shall be
deemed constituted and concluded. Non-divisible fractions of shares shall be allocated to the First Right Holder first to accept the offer by way of notice to the chairman of the Company’s Supervisory Board. The date the respective notice of
acceptance is received by the chairman of the Supervisory Board shall be conclusive. 

 Sec. 5 

Exercise of a Further Right of First Refusal 
  

	1.	In the event that not all First Right Holders exercise their right pursuant to Sec. 4, the following shall apply: The First Right Holders who accepted the offer submitted to them shall also be entitled to accept in
addition the offer that was first made to the First Right Holders who decided not to exercise their rights of first refusal and therefore did not accept the offer addressed to them. Those First Right Holders, who, upon first notification, exercised
their right of first refusal in the first round, are entitled to exercise the rights of first refusal which were not exercised pursuant to Sec. 4 pro rata to their respective shareholding in the Company, including any shares acquired pursuant
to Sec. 4. 

  

	2.	 The chairman of the Supervisory Board shall advise the First Right Holders, who, pursuant to para. 1 are entitled to acquire further shares in the
Company by furnishing an additional acceptance notice, within one week after expiry of the period of notice set forth in Sec. 4 para. 3, as to the number of additional shares they shall be entitled to acquire. The chairman

  
 - 7 / 42 - 

	 	
of the Supervisory Board shall effect such notification by way of registered mail. Such notification shall constitute a valid offer to the First Right Holders concerned with respect to the sale
of the relevant number of shares stated subject to the terms set forth in Sec. 2 para. 2. 

  

	3.	First Right Holders seeking to exercise additional rights of first refusal are to declare their acceptance of such additional offer with respect to the number of shares offered in accordance with para. 2 by way of
written notice to the chairman of the Supervisory Board within two weeks as of the date on which they receive a notification pursuant to para. 2. 

  

	4.	Upon the notice of acceptance pursuant to para. 3 being received by the chairman of the Supervisory Board, a sale and purchase agreement between the Offeror and the respective First Right Holders shall be deemed
constituted and concluded. Non-divisible fractions of shares shall be allocated to the First Right Holder first to accept the offer by way of notice to the chairman of the Company’s Supervisory Board. The date the respective notice of
acceptance is received by the chairman of the Supervisory Board shall be conclusive. 

 Sec. 6 

Comprehensive Exercise of Rights of First Refusal 

Each of the rights of first refusal pursuant to Sec. 4 and 5 may only be exercised or waived by a Shareholder in whole (not in part), i.e.
to the total extent rights of first refusal exist and not with regard to a part of the shares offered to, and only with respect to all shares held by the respective Shareholder. 

Sec. 7 
 Non-Exercise of
Rights of First Refusal 
  

	1.	After expiry of the period of notice pursuant to Sec. 4 para. 3 or after expiry of the period of notice pursuant to Sec. 5 para. 3, respectively, the chairman of the Supervisory Board shall notify the Shareholders about
the extent to which the rights of first refusal have been exercised. Such notification is to be effected by way of registered mail. 

  

	2.	 In the event that Shareholders chose not to or fail to exercise their rights of first refusal for all of the shares offered, none of the sales
pursuant to Sec. 4 

  
 - 8 / 42 - 

 
para. 4 and Sec. 5 para. 4 will be effected and the Offeror shall within a period of two months after receipt of the Supervisory Board’s notification pursuant to para. 1 hereof be entitled
to sell the shares offered to the acquirer named in the notification pursuant to Sec. 2 and with respect to which rights of first refusal have not been exercised, thereby duly observing the provisions on the restraint on alienation (Sec. 13 below)
as well as Shareholders’ tag-along rights pursuant to Sec. 8. Such sale may, however, not be effected on terms which are more beneficial to the acquirer than the terms set forth in the notification pursuant to Sec. 2. The respective agreement
entered into between the Offeror and the respective acquirer is to be submitted immediately upon conclusion to the chairman of the Supervisory Board for his inspection. 

Sec. 8 
 Tag-Along Rights

  

	1.	Each Shareholder is entitled to demand from the Offeror, who pursuant to Sec. 7 para. 2 is entitled to sell shares to the acquirer named in the notification of offer pursuant to Sec. 2, that such Offeror co-sells
his shares in accordance with the terms and conditions set forth in the said notification of offer pursuant to Sec. 2, to the extent desired by the respective Shareholder, to the acquirer named in the said notification. Such tag-along right is to be
exercised by way of written notice, such notice setting forth the number and series of shares to be co-sold. The said notice is to be submitted to the chairman of the Company’s Supervisory Board at the latest one month after receipt of the
notification of the offer pursuant to Sec. 4 para. 1. Upon receipt of such notice, the Company shall, through the chairman of its Supervisory Board, inform the Offeror immediately in respect of the exercise of the tag-along rights and the number and
series of shares which are to be co-sold. The said notice is to be effected by way of registered mail. 

  

	2.	In the event that the acquirer named in the notification pursuant to Sec. 2 is not willing to acquire the shares from the Offeror and the shares, with respect to which tag-along rights have been exercised, save for
para. 4 hereinafter the Offeror shall be obliged to sell upon the respective request by the Preferred Shareholders who exercised their tag-along rights his and such shares, with respect to which tag-along rights have been exercised, in proportion to
the shareholding of the Offeror (with the shares, which are to be acquired by First Right Holders, not to be deducted) and the respective Preferred Shareholder who has exercised his tag-along right (taking into account his entire shareholding) in
accordance with the following provisions. 

  
 - 9 / 42 - 

	3.	The Offeror shall notify the chairman of the Supervisory Board prior to any sale and after receipt of the notice of the chairman of the Supervisory Board that tag-along rights have been exercised of the number of shares
the acquirer named in the notification pursuant to Sec. 2 is willing to purchase. The Company, by the chairman of its Supervisory Board, shall immediately inform the Preferred Shareholders who want to exercise their tag-along rights accordingly. In
the event the acquirer is not willing to acquire all shares with respect to which tag-along rights have been exercised the Shareholders who want their shares being co-sold have to declare vis-à-vis the chairman of the Supervisory Board within
three days after receipt of the information by the chairman of the Supervisory Board whether they require their shares to be sold on a pro-rata basis pursuant to para. 2 or the entire sale pursuant to para. 4. Such request must be made within three
days by the chairman of the Supervisory Board vis-à-vis the Offeror who shall be bound by such request. 

  

	4.	In the event that the acquirer named in the notification pursuant to Sec. 2 is a competitor of the Company or an undertaking associated with a competitor of the Company within the meaning of § 15 AktG the sale to
the acquirer shall only be allowed if the acquirer purchases all shares of the Preferred Shareholders who have exercised their tag-along rights if the respective Preferred Shareholders request so. Sentence 1 shall also apply if the acquirer holds
more than 50% of the share capital of the Company after such sale. For the purpose of sentence 2 any shares held by an undertaking associated with the acquirer within the meaning of § 15 AktG shall be deemed to be shares held by the acquirer.
In the event that the acquirer is not willing to acquire all shares which are required to be co-sold, the Offeror shall not be permitted to sell its shares. 

Sec. 9 
 Drag-Along
Rights 
  

	1.	 On the basis of a resolution at any time and from time to time by the holders of a simple majority of the votes pertaining to the Preferred Shares
Series C and the holders of a simple majority of the votes pertaining to all Preferred Shares in the Company (collectively “Investor Majority”), all Shareholders shall agree to sell and transfer their shares to a third party
acquirer (not affiliated to any of the Shareholders) who is willing to acquire 50 % or more 

  
 - 10 / 42 - 

	 	
of all shares in the Company pro rata to their shareholding in the Company and, subject to Sec. 10 below, under equal terms and conditions with due regard being given to the form of the
securities being sold by each of the Parties (the “Sale Transaction”). A share swap, contribution, consolidation or merger of the Company with or into any other corporation or other entity or person, or any other corporate
reorganization, after which the Shareholders immediately prior to such share swap, contribution, consolidation, merger or reorganization, will own 50 % or less of the voting power of the receiving or surviving legal entity immediately after
such share swap, contribution, consolidation, merger or reorganization, or any other transaction or series of related transactions by which 50 % or more of the Company’s voting power is transferred shall also be deemed a Sale Transaction;
the same shall apply to the disposal (including by way of exclusive irrevocable licensing) of 50 % or more of the tangible and intangible assets of the Company (calculated at fair market values and irrespective of whether such assets may be
shown in the Company’s financial statements under applicable generally accepted accounting principles). 

  

	2.	By way of a resolution of an Investor Majority, a person shall be appointed to negotiate the terms and conditions of the Sale Transaction with the third party acquirer (“Lead Negotiator”). The Lead
Negotiator shall ensure that (i) the Shareholders’ interest in achieving a high price as consideration for the Sale Transaction will be duly considered and (ii) the Shareholders only give representations and warranties that are
typical for the respective Sale Transaction and in relation to the respective class of shares sold thereunder. The Lead Negotiator shall not have the authority to bind the Shareholders or the Company. The negotiations of the Lead Negotiator shall at
any time be subject to review and approval by an Investor Majority. 

  

	3.	All Shareholders shall take all actions necessary and desirable in connection with the consummation of a Sale Transaction, including to (i) participate in the Sale Transaction by entering into the contract with the
acquirer at the terms and conditions agreed upon by an Investor Majority, (ii) approve the terms of any such Sale Transaction and such matters ancillary thereto as may be necessary or appropriate in the judgment of an Investor Majority to
effect such Sale Transaction, (iii) waive any appraisal or dissenters rights that such Shareholder would have with respect to such Sale Transaction, and (iv) not block or prevent the consummation of a Sale Transaction. 

 

	4.	Secs. 2 to 8 and 13 of this Agreement shall not apply to any transaction under this Sec. 9. This Sec. 9 shall take precedence over Sec. 14 below and Sec. 23 para. 3 of the Articles of
Association of the Company. 

  
 - 11 / 42 - 

 Sec. 10 

Liquidation Preference / Sale Proceeds / Dividends / Conversion 
  

	1.	Any event of 

  

	 	a.	a liquidation, dissolution or winding up of the Company; or 

  

	 	b.	a share swap, contribution, merger, consolidation, reorganization or similar transaction or series of related transactions of the Company with or into another entity which results in the voting securities of the Company
outstanding immediately prior thereto representing immediately thereafter 50 % or less of the combined voting power of the voting securities of the receiving or surviving legal entity outstanding immediately after such share swap, contribution,
merger, consolidation, reorganization or similar transaction but excluding any transaction or series of transactions principally for bona fide equity financing purposes in which the Company issues new securities primarily for cash or the
cancellation or conversion of indebtedness of the Company or a combination thereof for the purpose of financing the operations and business of the Company; or 

  

	 	c.	a sale, lease or other conveyance (including by way of exclusive irrevocable licensing) of 50 % or more of the tangible and intangible assets of the Company (calculated at fair market values and irrespective of
whether such assets may be shown in the Company’s financial statements under applicable generally accepted accounting principles); or 

  

	 	d.	a sale of shares in the Company, in a single transaction or series of related transactions, representing at least 50 % of the voting power of the voting securities of the Company 

shall be deemed an “Exit Event”, unless an Investor Majority with the approval of OrbiMed Private Investments III, LP and
OrbiMed Associates III, LP (jointly “OrbiMed”) waives such qualification as an Exit Event (i.e. the proceeds will be distributed among the Shareholders on a pro rata basis). In case of the transformations of legal form
(formwechselnde Umwandlungen) pursuant to the German Act on the Transformation of Companies 

  
 - 12 / 42 - 

	 	
(Umwandlungsgesetz, UmwG), no Exit Event shall be deemed; provided, however, that the rights of the Shareholders under this Agreement, the Investment Agreement and the Articles of
Association shall continue to apply without any changes or amendments. 

  

	2.	In case of an Exit Event, the proceeds net of transaction costs and after repayment of the silent partnerships which become due upon the Exit Event including remuneration due thereon (the “Proceeds”)
shall be distributed among the Shareholders as follows: 

  

	 	a.	The Proceeds are first to be paid to the Holders of Preferred Shares Series C up to an amount per each Preferred Share Series C held by them, respectively, which corresponds to 2.5 times the Original Issue Price Series
C (as adjusted pursuant to Sec. 1 para. 3 and 4) plus an 8 % annual cumulative interest thereon. Should the Proceeds be less than the amount required in accordance with the foregoing, the whole Proceeds shall be distributed among the
Holders of Preferred Shares Series C in the ratios of their relevant shareholding in Preferred Shares Series C. 

  

	 	b.	After the payments pursuant to lit. a, up to 3.5 % of the remaining Proceeds shall be paid to the Beneficiaries being entitled under the Carve Out Plan (each as defined in Sec. 22 below). 

 

	 	c.	After the payments pursuant to lit. a and b, the remaining Proceeds shall be paid to the Holders of Preferred Shares Series B up to an amount which corresponds to one time their respective total contributions
(total issue price plus any contributions to the capital reserves of the Company pursuant to § 272 para. 2 HGB; the “Total Contributions”) on their respective Preferred Shares Series B plus an 8 % annual cumulative
interest thereon. Sentence 2 of lit. a shall apply accordingly among the Holders of Preferred Shares Series B in respect of their relevant shareholding in Preferred Shares Series B. 

 

	 	d.	 After the payments pursuant to lit. a to c, the remaining Proceeds shall be paid to the Holders of Preferred Shares
Series A-1 in respect of the Preferred Shares Series A-1 registered with the commercial register on September 14, 2007 (2nd tranche) up to an
amount which corresponds to two times their respective Total Contributions on their respective Preferred Shares Series A-1 registered with the commercial register on September 14, 2007 (2nd
tranche) (i.e. EUR 74.00 per such Preferred Share Series A-1). Sentence 2 of lit. a shall apply accordingly among the Holders of Preferred Shares Series A-1 

  
 - 13 / 42 - 

	 	
in respect of their relevant shareholding in Preferred Shares Series A-1 registered with the commercial register on September 14, 2007
(2nd tranche). 

  

	 	e.	After the payments pursuant to lit. a to d, the remaining Proceeds shall be paid to the Holders of Preferred Shares Series A-1 in respect of the Preferred Shares Series A-1 registered with the commercial register on
December 14, 2006 (1st tranche) up to an amount which corresponds to one time their respective Total Contributions on their respective Preferred Shares Series A-1 registered with the
commercial register on December 14, 2006 (1st tranche). Sentence 2 of lit. a shall apply accordingly among the Holders of Preferred Shares Series A-1 in respect of their relevant
shareholding in Preferred Shares Series A-1 registered with the commercial register on December 14, 2006 (1st tranche). 

 

	 	f.	After the payments pursuant to lit. a to e, the remaining Proceeds shall be paid to the Holders of Preferred Shares Series A up to an amount which corresponds to one time their respective Total Contributions on their
respective Preferred Shares Series A and, additionally, to BioM Aktiengesellschaft Munich BioTech Development up to an amount of EUR 231,373, to TransConnect Unternehmensberatungs- und Beteiligungs AG up to an amount of EUR 231,373 as well
as to MAPO Beteiligungsgesellschaft mbH up to an amount of EUR 120,251 (it being understood that the Total Contributions on the Preferred Shares Series A shall not include the contribution to the capital reserves of the Company by BioM Venture
Capital GmbH & Co. Fonds KG and TransConnect Unternehmensberatungs- und Beteiligungs AG of the accumulated interest on their respective bridge loan, i.e. BioM Venture Capital GmbH & Co. Fonds KG’s and TransConnect
Unternehmensberatungs- und Beteiligungs AG’s waiver of their claims to accumulated interest for the bridge loan to the Company’s capital reserves shall not be regarded as investment entitling to a preference payment). Sentence 2 of lit. a
shall apply accordingly among the Holders of Preferred Shares Series A. 

  

	 	g.	The Proceeds remaining after the payments pursuant to lit. a to f (if any) shall be distributed amongst all Shareholders proportionate to their respective total shareholding in the Company. 

  
 - 14 / 42 - 

	3.	In the event that the Proceeds of an Exit Event consist of shares listed on a stock exchange, the share price, as listed, at the time of the consideration effectively being paid shall be conclusive. In any other case,
to the extent that the value of the shares received is material, such value shall, with binding effect on all Shareholders, be determined by the Company’s auditor for the purpose of the respective application of para. 2. 

 

	4.	In the event of any dividend or other distribution by the Company to its shareholders, the respective distributions shall be divided among the Shareholders in the same way as the Proceeds of an Exit Event in accordance
with the liquidation and sale preference set forth in para. 2 above (“Preferred Dividends”). In a subsequent Exit Event, the liquidation and sales preferences set forth in para. 2 above shall be reduced by the amounts received as
Preferred Dividend, respectively. Upon demand of an Investor Majority, the net proceeds of any payment resulting from a disposal of assets of the Company or resulting from a licensing, collaboration or partnering transaction entered into after the
date of this Agreement (but excluding, for the avoidance of doubt, proceeds resulting from issuing shares of the Company and FTE payments), provided that such proceeds exceed USD 5,000,000, shall be distributed as a dividend to the shareholders
of the Company and distributed as set forth in this para. 4 and Sec. 5b para. 3 of the Articles of Association of the Company. 

  

	5.	Each Preferred Shareholder is entitled to demand from the other Shareholders at any time that the shares held by him be converted, whether individually or in total, into Common Shares at a ratio of 1:1. The Preferred
Shareholders are obliged to co-operate in effecting the conversion of all Preferred Shares held by them into Common Shares at a ratio of 1:1 in the event of (i) the closing of a firmly committed underwritten public offering of shares in the
Company or a holding company at a price per share to the public of at least five times the Original Issue Price Series C (as adjusted pursuant to Sec. 1 para. 3 and 4) and with net proceeds to the Company or the holding company of not less
than EUR 20,000,000 (“Qualified IPO”), or (ii) a resolution of an Investor Majority with the approval of OrbiMed in favor of said conversion. The Preferred Shareholders shall be reinstated into their position prior to the
conversion, if the Qualified IPO or the IPO does not occur within 90 days after the conversion. 

  

	6.	 In the event of a direct or indirect (via a holding company) listing of the Company and/or shares in the Company and/or the public offering of the
Company’s shares on a stock exchange in the European Union, Switzerland, 

  
 - 15 / 42 - 

	 	
a transnational stock exchange, the New York Stock Exchange or NASDAQ (“IPO”), the Shareholders undertake to do or cause to be done everything necessary or appropriate, in
particular, (i) in case of a direct IPO, by way of a transfer of shares in the Company held by them, respectively, without compensation to each other or, (ii) in case of an indirect IPO via a holding company, by way of an exchange between
the shares in the Company held by them, respectively, and the common shares in the holding company (at different exchange ratios applying to shares of different classes of the Company), so that after such measures each Shareholder holds such
participation in the share capital of the Company or the holding company that the value of the shares held by each Shareholder (according to the price per share sold to the public in the IPO) corresponds to the amount each Shareholder would be
entitled to under para. 2 above in the event of a sale of 100 % of the shares of the Company at such price per share. 

Sec. 11 
 Unrestricted
Transfer to Associated Undertakings 
  

	1.	Each Shareholder shall be entitled to transfer its shareholding in the Company wholly or partly to a limited liability company which is 100 % owned by such Shareholder, provided that the original Shareholder shall
remain liable for the transferee’s performance of all of the original Shareholder’s obligations under this Agreement; Sec. 13 below shall apply accordingly. 

 

	2.	Each of the Preferred Shareholders shall be entitled to transfer all or part of its shareholding in the Company to any entity or fund controlled or managed by, controlling or managing, or under the common control or
management with, any such Preferred Shareholder. Further, each of the Preferred Shareholders shall be entitled to transfer its shareholding in the Company as part of a transfer of a portfolio of investments of a similar nature to a third party which
is predominantly managed by the same group of individuals having been responsible for managing such Preferred Shareholder’s shareholding in the Company prior to the transfer. With regard to the shareholding of The Global Life Science Ventures
fund(s), this unrestricted transfer shall especially apply to transactions between the funds The Global Life Science Ventures Fonds II GmbH & Co. KG and The Global Life Science Ventures Fund II LP. 

 

	3.	Sec. 2 to 9 shall not apply to transfers pursuant to the preceding paras. 1 and 2. 

  
 - 16 / 42 - 

 Sec. 12 

Succession 
  

	1.	If a Shareholder (including an Indirect Shareholder) dies, the rights and duties arising from or as a result of this Agreement shall be transferred to the heirs of such estate of such deceased Shareholder by way of
succession. 

  

	2.	In the event of the gift of shares in the Company by means of a legacy (Vermächtnis), the testator and the heirs shall make the transfer of such shares dependent upon the beneficiary of the legacy becoming
party to this Agreement and the Investment Agreement; Sec. 13 below shall apply accordingly. 

  

	3.	The preceding paras. 1 and/or 2 shall also apply if Prof. Skerra Beteiligungsgesellschaft mbH and/or MAPO Beteiligungsgesellschaft mbH are liquidated, merged or otherwise terminated. If they become insolvent, the
Company`s right to redeem the shares can be exercised at their calculated nominal value. 

 Sec. 13 

Transfer of Shares by Way of Singular Succession 
  

	1.	Shares, whether for or without consideration, may only be transferred by way of singular succession (Einzelrechtsnachfolge) if the acquirer has become a party in writing to this Agreement and the Investment
Agreement prior to or at the same time as the acquisition of the shares, with the rights and duties which correspond to those of its respective legal predecessor. 

 

	2.	The Parties hereby already now declare their consent, and hereby already now offer, to such future shareholder of the Company to become a party to this Agreement and the Investment Agreement and to such transferring
shareholder ceasing to be a party to this Agreement and the Investment Agreement, provided he transfers all of his shares, provided that such future shareholder acquires the shares in accordance with the provisions of this Agreement. Each of the
Parties, except the Company, waives the requirement that they are notified of such accession to and leaving of this Agreement and the Investment Agreement pursuant to § 151 sentence 1 German Civil Code (Verzicht auf den Zugang der Beitritts-
und Austrittserklärung gemäß § 151 Satz 1 BGB), which shall become effective upon receipt by the Company of a corresponding instrument duly executed in writing by the transferring and the future shareholder.

  

	3.	The foregoing shall not apply in respect of transfers in accordance with the terms and provisions set forth in Sec. 9 (Drag-Along Rights). 

  
 - 17 / 42 - 

 Sec. 14 

Veto Rights / Binding Voting Obligations / Liquidation 
  

	1.	Each of the Shareholders undertakes individually for himself vis-à-vis each other Shareholder, to resolve as part of a shareholders’ meeting of the Company the following resolutions only after an internal
vote amongst the Shareholders in which an Investor Majority has voted in favor of the passing of the resolution in the shareholders’ meeting: 

  

	 	a.	Amendment, alteration or change of the rights, preferences, or privileges of the Preferred Shareholders so as to adversely affect the Preferred Shares, provided that each Shareholder within each class is treated
equally; 

  

	 	b.	Any transformations of the Company (Umwandlungen) within the meaning of the German Act on Transformation of Companies (Umwandlungsgesetz, UmwG); 

 

	 	c.	Disposition of 50 % or more of the assets of the Company; 

  

	 	d.	Merger of the Company with another entity; 

  

	 	e.	Liquidation of the Company; 

  

	 	f.	Amendments to the Company’s Articles of Association, including but not limited to an amendment to (i) authorize, create, incur any obligation to issue or issue any shares of any class or series of shares
ranking on parity or senior to the Preferred Shares Series C with respect to voting rights, dividends, conversion, distributions upon liquidation of the Company or redemption rights; (ii) effect a liquidation of the Company or a corporate
reorganization of the Company; (iii) issue shares of Common Shares or increase the authorized number of shares of Common Shares, except for the purposes of (A) issuing shares upon exercise of outstanding options to purchase Common Shares
or warrants for the purchase of Common Shares; (B) issuing shares upon the conversion of Preferred Shares; or (C) issuing shares in connection with a stock split, stock dividend or other recapitalization; and (iv) increasing or
decreasing the size of the Supervisory Board or change the procedures by which members of the Supervisory Board are elected or appointed; 

  
 - 18 / 42 - 

	 	g.	Any action concerning the increase or reduction of the Company’s authorized share capital; 

  

	 	h.	Any authorization or issuance of any warrants or other debt securities giving a right to participate in the profits of the Company (Genussscheine), options or warrants; 

 

	 	i.	Any authorization in respect of the conclusion of corporate agreements within the meaning of §§ 291 et. seq. of the AktG; 

 

	 	j.	Any integration (Eingliederung) within the meaning of §§ 319 et. seq. of the AktG; 

  

	 	k.	Appointment of the Company’s auditors; 

  

	 	l.	Approval of the Company’s annual financial statements (Jahresabschlüsse) pursuant to § 173 of the AktG; 

  

	 	m.	Any actions regarding the purchasing or holding of the Company’s shares within the meaning of §§ 71 et. seq. of the AktG; 

 

	 	n.	Any actions regarding the repurchase or redemption of the Company’s shares; 

  

	 	o.	Any action regarding the declaration of dividends or the distribution of profits to shareholders. 

Respecting the statutory independence of the Management Board and the Supervisory Board, the Shareholders shall endeavor to ensure that
measures listed in lit. a. to o. above are undertaken at subsidiaries of the Company only after an internal vote amongst the Shareholders in accordance with the above provisions of this Sec. 14 para. 1, provided that such subsidiaries or their
activities have a significant economic importance for the Company. 
  

	2.	Each Shareholder shall vote his shares in respect of the matters set forth in para. 1 above in accordance with the decision of an Investor Majority and shall procure to take all measures required to not block or
prevent such decision of the Investor Majority. The foregoing sentence applies, in particular, without limitation, to any votes in shareholders’ meetings and any separate class votes (Sonderbeschlüsse), in each case in respect of
the matters set forth in para. 1 above. 

  
 - 19 / 42 - 

	3.	Each Preferred Share carries a number of votes equal to the number of Common Shares then issuable upon its conversion into Common Shares. Except as otherwise provided in para. 1 above or as otherwise required by law,
the Preferred Shareholders shall vote as a single class with the holders of Common Shares and each other class or series of voting shares of the Company on all matters to be acted upon by the shareholders of the Company. 

 

	4.	The Shareholders are obliged to resolve the Company’s liquidation in the event that the Company has sold at least 50 % of its assets (calculated at fair market value) or insolvency or similar proceedings have
been commenced in respect of assets of a company, in which a participation is held (Beteiligungsunternehmen) within the meaning of § 271 of the German Commercial Code (HGB) which comprises in total 50 % of all
Company’s assets (calculated at fair market value), or in the event that the foregoing are liquidated. 

 Sec. 15

 Company’s Approval 
  

	1.	In order to secure that the shares subject to the terms and provisions of this Agreement may only be transferred in accordance with such terms and provisions, the Company’s shares’ transferability is
restricted (vinkuliert) pursuant to Sec. 7 of the Articles of Association. 

  

	2.	The Company is obliged to grant its consent to the transfer of shares provided that the provisions of this Agreement pursuant to Sections 2 to 13 have been fully complied with. In the event that an Offeror has given a
notification of offer pursuant to Sec. 2 and in the event that a Shareholder has exercised a right of first refusal, the consent may only be granted for a transfer of shares from the Offeror to the First Right Holders and, in the event of rights of
first refusal not being exercised, only in respect of a transfer of shares to the acquirer named in the notification pursuant to Sec. 2 para. 2. 

Sec. 16 
 Members of the
Supervisory Board 
  

	1.	The Company’s Supervisory Board shall consist of three members. 

  
 - 20 / 42 - 

	2.	The Shareholders will exercise their voting rights in elections of members of the Supervisory Board as follows: 

  

	 	a.	One member of the Supervisory Board shall be nominated by OrbiMed Private Investments III, LP; 

  

	 	b.	One member of the Supervisory Board shall be jointly nominated by the Holders of Preferred Shares Series B, Holders of Preferred Shares Series A-1 and Holders of Preferred Shares Series A with a simple majority of the
votes pertaining to the Preferred Shares Series B, Preferred Shares Series A-1 and Preferred Shares Series A; 

  

	 	c.	The third member of the Supervisory Board shall be an independent industry expert jointly nominated by all Shareholders with a simple majority of the votes pertaining to all shares in the Company with OrbiMed Private
Investments III, LP in the affirmative. 

  

	3.	To the extent the right to nomination pursuant to para. 2 is not exercised, the concerned member(s) of the Supervisory Board shall be appointed by a majority vote of the shareholders’ meeting (one share giving one
vote). 

  

	4.	The Shareholders will exercise their voting rights accordingly with respect to the dismissal of a member of the Supervisory Board who had been nominated by the respective Shareholders which is proposed by such
respective Shareholders and with respect to the election of such person nominated by the respective Shareholders in the dismissed member’s stead. 

  

	5.	The Supervisory Board shall hold a meeting at least four times per year. It is the understanding of the Parties that members of the Supervisory Board should meet the Management Board two times per year in addition to
the four formal Supervisory Board meetings for review and discussion of the further development of the Company’s business. 

  

	6.	Any necessary and reasonable out-of-pocket expenses incurred in the course of the members of the Company’s Supervisory Board’s performance of their duties, in particular travel expenses, shall be reimbursed to
the respective members by the Company. In addition, the independent industry expert nominated pursuant to para. 2 lit. c. shall receive an appropriate remuneration for his / her services as a member of the Supervisory Board. 

 

	7.	 The Holders of Preferred Shares Series B, Holders of Preferred Shares Series A-1 and Holders of Preferred Shares Series A shall have the right to
jointly nominate one non-voting observer to the meetings of the Supervisory Board with a simple majority of the votes pertaining to the Preferred Shares Series B, Preferred Shares Series A-1 and Preferred Shares Series A. In

  
 - 21 / 42 - 

	 	
addition, the Holders of Preferred Shares Series C shall have the right to jointly nominate one non-voting observer to the meetings of the Supervisory Board with a simple majority of the votes
pertaining to the Preferred Shares Series C. The Company shall provide to such observers copies of all documents and information given to the members of the Supervisory Board in connection with such meetings. Such observers shall be bound by the
same secrecy obligations as the members of the Supervisory Board. 

 Sec. 17 

Public Offering 
  

	1.	On the basis of a resolution in favor of an IPO by an Investor Majority, each of the Preferred Shareholders shall have the right to demand from the Company and all Shareholders that an IPO be effected. In the event that
such IPO requires restructuring measures to be taken in respect of the Company (e.g. the transfer of the Company’s shares to a holding company against issue of such company’s shares), the Shareholders shall be obliged, subject to the
condition set forth in sentence 1 hereof, to grant their consent to such restructuring measures being taken and to submit all other required declarations (e.g. contributing, transferring, assigning and/or delivering their shares of the Company to
said holding company in exchange and consideration for such company’s shares), provided, however, that such share swap, exchange or contribution shall take into account the provisions of Sec. 10 para. 6 above and that, as a result of the
foregoing, the Shareholders shall not suffer any unreasonable tax disadvantages or other material detriments unless the Shareholders are adequately compensated for such disadvantages or detriments. 

 

	2.	Upon rightful demand by Preferred Shareholders, the Company shall initiate the proceedings for the IPO and shall bear all costs and expenses (including banks’ commissions and fees) related thereto. The Company
shall also bear the costs and expenses of the legal adviser retained by the Preferred Shareholders in relation to such IPO. 

  

	3.	All Shareholders undertake, in the event of the Company’s shares being listed in the course of an IPO, in accordance with the terms of this Sec. 17, to fully comply with conditions and restrictions applicable under
relevant Blue Sky Laws or lock-ups demanded by investment or other banks. 

  

	4.	 All Shareholders furthermore undertake to comply with all regulations and take all actions required in order to procure and not to block or prevent a

  
 - 22 / 42 - 

	 	
listing of shares, including, but not limited to, submitting a declaration to the effect that such Shareholder shall not dispose of his shares during the lock-up period or transferring his shares
to a depository account of Clearstream Banking Aktiengesellschaft or otherwise. 

  

	5.	Six months after the effective date of an IPO, holders of Preferred Shares (also after conversion into Common Shares) (the “Registrable Securities”) shall have the following rights (all such rights,
collectively, the “Registration Rights”): 

  

	 	a.	Holders of at least 51 % of the Registrable Securities may request that the Company files a registration statement covering the sale of Registrable Securities then outstanding resulting in net offering proceeds of
at least EUR 10,000,000 (“Demand Rights”). Upon such request, the Company will prepare and file a registration statement and otherwise use its best efforts to cause such shares to be registered under the Securities Act of 1933, as
amended, or other applicable laws governing the registration of such securities on a stock exchange in the European Union, Switzerland or a transnational stock exchange within 90 days of the request. The holders of Registrable Securities will be
limited to three such demand rights and no demand may be sooner than 12 months from the prior demand. 

  

	 	b.	The holders of Registrable Securities shall be entitled to “piggyback” Registration Rights on all registrations of the Company (“Piggyback Rights”) excluding any registration solely in
connection with an employee benefit or stock ownership plan. The holders of Registrable Securities may be cut back completely on the Company’s IPO but may only be cut back to not less than 25 % of the total offering by the underwriters,
and then only after all persons who do not hold Registration Rights are first cut back. For secondary registrations on behalf of holders of the Company’s securities (other than the holders of Registrable Securities pursuant to Demand Rights
pursuant to lit. a.), holders who do not hold Registration Rights shall be cut back first, then holders of Registrable Securities who did not request such registration shall be cut back and then the holders requesting such registration. Cut backs at
each level shall be made ratably among the applicable holders on the basis of the number of shares owned by each such holder. 

  

	 	c.	 From and after the first anniversary of the Company’s IPO, holders of Registrable Securities shall be entitled to registrations on Form S-3 (if

  
 - 23 / 42 - 

	 	
available to the Company) provided that the anticipated aggregate public offering price of all securities of the Company to be sold in such registered offering would exceed EUR 1,000,000
(“S-3 Rights”). The Company shall not be obligated to effect more than two such registrations in any 12-month period. 

  

	 	d.	The Company shall bear the registration expenses (exclusive of underwriting discounts and commissions) of the demand registrations, piggyback registrations and S-3 registrations described above. 

 

	 	e.	 The Registration Rights may be transferred to a transferee or assignee acquiring at least 100,000 shares of Registrable Securities (equitably adjusted
for any stock splits, subdivisions, stock dividends, changes, combinations or the like); provided, however, that (i) the Company must receive written notice prior to the time of said transfer, stating the name and address of said transferee or
assignee and identifying the securities with respect to which such rights are being assigned, (ii) the transferee or assignee of such rights must not be a person deemed by the Supervisory Board of the Company, in its reasonable judgment, to be
a competitor or potential competitor of the Company, and (iii) such transferee or assignee must agree to be bound by the terms of the registration rights agreement. Notwithstanding the limitation set forth in the foregoing sentence respecting
the minimum number of shares which must be transferred, any holder that (i) is a partnership, limited liability company or corporation may transfer such holder’s Registration Rights to (A) entities affiliated directly or indirectly
with such partnership or its manager, limited liability company or corporation, (B) any partner (or retired partner or incoming partner), member (or retired member) or stockholder of such partnership, limited liability company or corporation,
(C) the spouse, siblings, lineal descendants or ancestors of any such partner (or retired partner), member (or retired member) or stockholder, (D) the estate of any such partner (or retired partner), member (or retired member) or
stockholder and (E) any custodian or trustee for the benefit of any such partner (or retired partner), member (or retired member) or stockholder or the spouse, siblings, lineal descendants or ancestors of any such partner (or retired partner),
member (or retired member) or stockholder, as the case may be, or (ii) holds shares in its capacity as trustee, manager or custodian of a trust, may transfer such holder’s Registration Rights to a replacement

  
 - 24 / 42 - 

	 	
trustee, manager or custodian of the relevant trust, in each case, without restriction as to the number or percentage of shares acquired by any such transferee. 

 

	6.	Registration Rights will terminate (i) 5 years after an IPO or (ii) as to any holder, such time at which all Registrable Securities held by such holder can be sold in any three-month period without
registration in compliance with Rule 144 Securities Act of 1933, as amended, without volume limitations and without reliance on Rule 144(k) Securities Act of 1933, as amended, or other applicable laws governing the sale of unregistered securities of
a corporation registered on a stock exchange in the European Union or a transnational stock exchange. 

 Sec. 18 

Auditors 
 The Shareholders
shall appoint a nationally recognized auditing company as auditor of the Company and undertakings associated with it. 
 Sec. 19 

Information Rights; Covenants 
  

	1.	The Company shall be obliged to provide each holder of Preferred Shares and each holder of Common Shares holding 1 % or more of the total outstanding shares and Technologie Beteiligungsfonds Bayern II
GmbH & Co. KG (“TF II”) with the following information: 

  

	 	a.	audited annual accounts within 120 days from the end of the respective business year; 

  

	 	b.	unaudited monthly profit and loss and cash-flow accounts within 30 days from the end of the respective month as well as research and development reports on current material development projects. 

 

	2.	In addition, the Company shall be obliged to provide each holder of Preferred Shares holding at least 10,000 Preferred Shares (as adjusted for stock splits, stock dividends, reverse stock splits and the like with
respect to such shares) with the following information: 

  

	 	a.	 annual business plan / budget for the subsequent business year following approval by the Supervisory Board of the Company, but in

  
 - 25 / 42 - 

	 	
no event later than 30 days prior to the end of the current business year and any update of the annual business plan as such update is prepared; 

 

	 	b.	unaudited quarterly accounts and reports within 30 days from the end of the respective quarter explaining inter alia the business development, progress in research and development, staff changes and any other major
issues, in each case against the business plan and / or the agreed budget. 

 Moreover, the Company shall be obliged to provide
each Preferred Shareholder holding 10 % or more of the total share capital of the Company on a fully-diluted basis management reports prepared by the Management Board of the Company for meetings of the Supervisory Board prior to each such
meeting; provided, however, that the Company shall not be obligated to provide such management reports if it reasonably believes that this action could erode trade secret status of such information. 

 

	3.	The Company shall permit any Preferred Shareholder holding at least 10,000 Preferred Shares (as adjusted for stock splits, stock dividends, reverse stock splits and the like with respect to such shares), to visit and
inspect the Company’s properties, to examine its books of account and records and to discuss the Company’s affairs, finances, and accounts with its officers, all at such reasonable times as may be requested by such holder; provided,
however, that the Company shall not be obligated pursuant to this para. 3 to provide any information which it reasonably considers to be a trade secret or confidential information. The requesting Shareholder bears all costs of this process.

  

	4.	Such information rights as set forth above may be transferred to acquirers of Preferred Shares provided that such transfer of rights has been notified to the Company at least two weeks prior to the relevant information
having to be submitted. 

  

	5.	 The individuals who are parties to this Agreement (“Affected Persons”) agree that the Company, its corporate bodies, the members thereof
and its Shareholders as well as all business entities which are affiliated with the Shareholders within the meaning of § 15 AktG (“Recipients”) may, in compliance with applicable legal provisions, manually or electronically store,
process or exchange among themselves personal data of the Affected Persons. This applies without limitation to personal data which serve for the purpose of identification of the Affected

  
 - 26 / 42 - 

	 	
Persons (e.g. name, profession, address, date of birth) as well as for such personal data as may have a bearing on the acquisition, the holding or the disposition of the participation in the
Company or the commercial basis or merits of these business transactions. Subject to existing confidentiality agreements, if any, the Recipients may also transfer personal data of the Affected Persons to Recipients or to persons acting on behalf of
any Recipient in other member states of the European Union, the agreement of the European Economic Area or in third countries, provided that a reasonable level of data protection is ensured at the Recipients in such third countries.

  

	6.	Pursuant to the German Prevention of Money Laundering Act (Geldwäschegesetz - GWG), TF II is obliged to identify the Shareholders and – as the case may be - possible legal successors of such
Shareholders. In order to fulfill the requirements imposed by the GWG, the Shareholders and – as the case may be – possible legal successors of such Shareholders hereby undertake vis-à-vis TF II, respectively, to use commercially
reasonable efforts to provide TF II with a copy of their passports (individual person) or an excerpt from the competent commercial register including a list of shareholders (legal entity) or – in case of foreign legal entities – comparable
documents and – insofar as existent – to identify the beneficial owner of such Shareholder. The Shareholders undertake to provide TF II with the aforementioned documents until the date of accession of each such Shareholder as a party to
the Investment Agreement and this Agreement. 

  

	7.	 The Company will use, and cause each direct and indirect subsidiary to use, commercially reasonable efforts to conduct its affairs such that the
Company and its direct or indirect subsidiaries will not be a “passive foreign investment company” (“PFIC”) as defined in Section 1297 of the Internal Revenue Code of 1986, as amended (the “Code”) for
the current year or any subsequent year. The Company agrees to make available to any Preferred Shareholder upon request, the books and records of the Company and its direct and indirect subsidiaries, and to provide information to such Preferred
Shareholder with respect to the Company’s or any subsidiary’s status or potential status as a PFIC. The Company will make due inquiry with its tax advisors on at least an annual basis regarding its status as a PFIC. Upon a determination by
the Company, any Preferred Shareholder or any taxing authority that the Company or any direct or indirect subsidiary has been or is likely to become a PFIC, the Company will provide any Preferred Shareholder with all information reasonably available
to the Company or any of its subsidiaries to permit such Preferred Shareholder to (i) accurately prepare all Tax returns and comply with any reporting requirements as a result of such determination and (ii) make any election (including,
without 

  
 - 27 / 42 - 

	 	
limitation, a “qualified electing fund” election under Section 1295 of the Code), with respect to the Company or any of its direct or indirect subsidiaries, and comply with any
reporting or other requirements incident to such election. If a determination is made by the Company, any Preferred Shareholder or any taxing authority that the Company is a PFIC for a particular year, then for such year and for each year
thereafter, the Company will also provide the Preferred Shareholders with a completed “PFIC Annual Information Statement” as required by Treasury Regulation Section 1.1295-1(g) and otherwise comply with applicable Treasury Regulation
requirements. The Company will promptly notify the Preferred Shareholders of any assertion by the Internal Revenue Service that the Company or any of its direct or indirect subsidiaries is or is likely to become a PFIC. 

 

	8.	The Company will not sell or issue any shares of the Company to any U.S. person or entity if such sale or issuance of shares would cause the Company to be a “controlled foreign corporation”
(“CFC”) within the meaning of Section 957 of the Code. The Company will provide prompt written notice to the Preferred Shareholders if at any time the Company becomes aware that it or any subsidiary may, or has, become a CFC.
Upon request of a Preferred Shareholder from time to time, the Company will promptly provide in writing such information in its possession concerning its shareholders and, to the Company’s actual knowledge, the direct and indirect interest
holders in each shareholder sufficient for such Preferred Shareholder to determine that the Company is not a CFC. In addition, the Company will cooperate in good faith with the Preferred Shareholders and their tax advisors to take any and all
commercially reasonable actions as requested by the Preferred Shareholders to avoid becoming and to mitigate the impact on the Preferred Shareholders of becoming or being a CFC. The Company will promptly notify the Preferred Shareholders of any
assertion by the Internal Revenue Service that the Company or any of its direct or indirect subsidiaries is or is likely to become a CFC. 

  

	9.	In the event that a Preferred Shareholder’s tax advisor determines that such Preferred Shareholder’s interest in the Company is subject to the reporting requirements of either or both of Sections 6038 and
6038B of the Code, the Company agrees, upon a request from such Preferred Shareholder, to provide such information to such Preferred Shareholder as may be necessary to fulfil such Preferred Shareholder’s obligations under such requirements.

  

	10.	Each Shareholder hereby expressly consents to the provisions of this Sec. 19. 

  
 - 28 / 42 - 

 Sec. 20 

Future Financing Rounds / Pre-emption Rights 
  

	1.	Each of the Shareholders shall enter into investment agreements and shareholders’ agreements and related agreements for further rounds of financing of the Company (without the obligation to invest further funds),
provided that (i) such future financing agreements provide for reasonable and common terms and conditions, (ii) an Investor Majority agrees to the terms and conditions of the future financing agreements and (iii) each Shareholder
within each class is treated equally. 

  

	2.	As provided by mandatory German law, in any case of any increase of the Company’s capital the Preferred Shareholders shall have the mandatory right to maintain their percentage ownership in the Company. All
Shareholders shall waive their pre-emptive rights (Bezugsrechte) in the following events: 

  

	 	a.	Issues of the Preferred Shares Series C pursuant to the Investment Agreement; 

  

	 	b.	Securities issued as a dividend or distribution with respect to the Preferred Shares; 

  

	 	c.	Securities offered in an IPO as defined in Sec. 10 para. 6; 

  

	 	d.	Securities issued pursuant to the acquisition by the Company of another corporation or entity by consolidation, corporate reorganizations, or merger, or purchase of all or substantially all of the assets of such
corporation or entity as approved by the Company’s Supervisory Board; 

  

	 	e.	Securities issued to the Company’s officers, directors, employees, consultants, and advisors pursuant to stock option or employee incentive plans, agreements or arrangements as designated and approved by the
Company’s Supervisory Board; 

  

	 	f.	Securities issued without consideration pursuant to a stock dividend, stock split, or similar transaction approved by the Company’s Supervisory Board; and 

 

	 	g.	Securities issued in connection with equipment leasing, real estate leasing, bank financing or similar transactions approved by the Company’s Supervisory Board. 

  
 - 29 / 42 - 

	3.	The Parties agree that to the extent pre-emption rights with respect to shares to be newly issued are not exercised by any Party the other Shareholders shall be entitled to subscribe for the new shares with respect to
which pre-emption rights are not exercised on a pro-rata basis before a right to subscribe for such new shares shall be granted to any third party. 

Sec. 21 
 Additional
Undertakings, Prohibition to Compete, D & O Insurance 
  

	1.	Any inventions made by the persons named in Exhibit A as founder (the “Founders”) in the area of anticalin® proteins and/or lipocalins and (in both cases) modifications thereof and/or related
respective know-how shall exclusively be owned by the Company. Each of the Founders hereby undertakes to transfer the respective inventions, intellectual property rights and know-how to the Company free of any consideration. Each of them hereby
assigns such rights to the Company, which accepts such transfer. In order to obtain - to the extent possible – exclusive rights to inventions made during the employment at universities or other research institutes, the Founders will use their
best efforts to enforce their rights provided under the Act of Employees Inventions (Arbeitnehmererfindergesetz) in order to enable the Company to make use of such inventions in the most favorable way. 

 

	2.	 The Shareholders shall maintain complete secrecy in relation to confidential information and secrets of the Company, namely trade and business
secrets, of which they obtain knowledge, including without limitation the contents of this Agreement and the Investment Agreement, unless otherwise required by mandatory law. The Company, however, authorizes each of the Preferred Shareholders to
notify (i) undertakings affiliated with the respective Preferred Shareholder within the meaning of § 15 AktG, (ii) equity funds managed or advised by the respective Preferred Shareholder, a company affiliated with the respective
Preferred Shareholder within the meaning of § 15 AktG, a general partner and/or management company of the respective Preferred Shareholder, and (iii) the stock exchanges and any state offices and authorities to whom the respective
Preferred Shareholder or undertakings affiliated with him must notify this information under statutory provisions, about information concerning the Company to which they have access as shareholders of the Company, including without limitation the
contents of this Agreement and the Investment Agreement. In addition each of the Preferred Shareholders and undertakings affiliated with the respective Preferred Shareholder may officially publish such information, if he or undertakings

  
 - 30 / 42 - 

	 	
affiliated with the respective Preferred Shareholder are obliged to do so by statutory provisions or to stock exchanges or to any other authority to whose supervision he or undertakings
affiliated with him are subject. Technologie Beteiligungsfonds Bayern II GmbH & Co. KG and KfW shall be allowed to disclose their participations in the Company vis-à-vis the Federal Supervisory Agency (Bundesrechnungshof) and
the Federal Department of Economics (Bundeswirtschaftsministerium) as required by applicable law. 

  

	3.	As long as a Founder is a shareholder with at least 1.5 % in the Company’s share capital he undertakes not to directly or indirectly compete with the Company or its affiliates within (i) the business
field in which the Company and/or its affiliates are active on the day of this Agreement and (ii) the territory of the Federal Republic of Germany and every other country in which the Company and/or any of its affiliates operate on the day of
this Agreement. He shall also not be allowed to take a direct or indirect shareholding in a competing business. Shareholdings in other companies up to the amount of 2 % of the share capital are allowed as long as such shareholding does not
grant any influence on the management of the respective company and only pursues private asset management purposes. 

  

	4.	Each Founder who is employed by the Company hereby undertakes in his capacity as shareholder not to directly or indirectly compete with the Company or its affiliates within (i) the business field in which the
Company and/or its affiliates are active on the day of this Agreement and (ii) the territory of the Federal Republic of Germany and every other country in which the Company and/or any of its affiliates operate on the day of this Agreement for a
period of 12 months after the termination of his employment. In case of an infringement of the prohibition to compete pursuant to paras. 3 or 4 a penalty of EUR 10,000 per one single infringement is due. As one single infringement in this sense
is regarded a time period of one to fourteen calendar days. The right to demand injunctive relieve or damages shall not be affected hereby. 

  

	5.	 Paras. 3, 4 and 5 shall also apply when the Founder is only a consultant to the Company. As long as he is a shareholder in the Company, the Founder
Prof. Dr. Arne Skerra will not render any consultant services to another business entity which is active in the area of anticalin® proteins and/or lipocalins and/or (in both cases) modifications thereof. Furthermore, Prof. Dr. Arne
Skerra and the Company hereby agree to terminate the existing consultant agreement dated December 19, 2001 as amended by amendment agreement dated December 19/20, 2004 (jointly “Consultancy Agreement”)

  
 - 31 / 42 - 

	 	
with effect as of September 30, 2015 (“Termination Date”). Until the Termination Date, the Consultancy Agreement shall continue on a fully exclusive basis according to the
terms and provisions set forth in the Consultancy Agreement. Prof. Dr. Arne Skerra and the Company hereby acknowledge that the Consultancy Agreement will cease to be in force and effect after the end of the Termination Date, if the Consultancy
Agreement does not provide for the survival of specific provisions following its termination. 

  

	6.	Each Founder undertakes not to make any disparaging statement or derogatory comment in public and/or to any third party about the Company and/or its business or affairs and/or any of its directors, officers, employees
or shareholders in relation to the Company, its business or affairs. 

  

	7.	At its expenses, the Company shall obtain an adequate D & O insurance for the members of the Supervisory Board and board of management. 

Sec. 22 
 Management and
Founder Carve Out 
  

	1.	In addition to the existing employee stock option plan, the Company will implement a carve out plan in favor of (i) selected members of the management of the Company and (ii) Prof. Skerra
Beteiligungsgesellschaft mbH (jointly “Beneficiaries”) entitling the Beneficiaries to an amount representing up to 3.5 % of the Proceeds resulting from an Exit Event and remaining after the payments pursuant to Sec. 10
para. 2 lit. a in accordance with Sec. 10 para. 2 lit. b (“Carve Out Plan”). The detailed structure and the terms and conditions of the Carve Out Plan as well as the Beneficiaries and their respective entitlement shall
require the approval of an Investor Majority, whereby Prof. Skerra Beteiligungsgesellschaft mbH shall be entitled to a percentage of 7.14 % of the 3.5 % of the Carve out Plan (i.e. a total percentage of 0.25% of the Proceeds remaining
after the payments pursuant to Sec. 10 para. 2 lit. a). The Carve Out Plan shall be administered by the Supervisory Board. 

  

	2.	The details of the Carve Out Plan shall be laid down in a resolution of the Supervisory Board of the Company that has to be approved by an Investor Majority. The Shareholders undertake individually vis-à-vis each
other to resolve everything necessary and to make declarations to implement the Carve Out Plan as approved by an Investor Majority. 

  

	3.	Each of the Parties undertakes individually for himself vis-à-vis each other Party, to do or cause to be done everything necessary or appropriate to implement the Carve Out Plan, and in particular to exercise his
voting rights in the shareholders’ meeting of the Company. 

  
 - 32 / 42 - 

 Sec. 23 

Term of this Agreement 
  

	1.	This Agreement shall become valid and binding at the date of this Agreement and shall continue to be valid and binding until December 31, 2028; for this period of time, a regular termination (ordentliche
Kündigung) of this Agreement shall be excluded. Thereafter, each of the Parties may give six months’ written notice to the end of a calendar year to terminate its participation in this Agreement for the future. The right to terminate
this Agreement for cause (aus wichtigem Grund) shall remain unaffected. If one Party leaves as a result of giving notice or for any other reason, this Agreement shall be continued by the remaining Parties; this shall also apply in the event
of the insolvency or liquidation of any of the Parties. 

  

	2.	Upon this Agreement taking effect, all Existing Agreements, in particular the Consolidated Shareholders‘ Agreement 2012 dated November 12, 2012 as well as any and all other shareholders’ agreements and/or
investment agreements and/or comparable agreements among all or individual Shareholders relating to their participation in the Company, shall be totally replaced by this Agreement and the Investment Agreement for the future. The Loan Agreements
shall terminate and be of no further force or effect upon the effectiveness of the assignment of the Repayment Claims by the Lending Shareholders to the Company in accordance with Sec. 2 of the Investment Agreement. This para. 2 shall not
affect the cooperation agreements of the Company currently in effect with (i) KfW or Technologie Beteiligungsfonds Bayern II GmbH & Co. KG respectively and (ii) The Global Life Science Ventures Fonds II GmbH & Co. KG and
The Global Life Science Ventures Fund II Limited Partnership, respectively, i.e. these cooperation agreements shall not be terminated or replaced by this Agreement. 

 

	3.	This Agreement shall – with the exception of the provisions set forth in Secs. 10 para. 6 and 17 para. 5 and 6 – terminate at such date at which the Company’s shares or securities replacing
shares (e.g. American Depositary Receipts or DIs) are listed on a domestic or foreign or transnational stock exchange; the foregoing shall also apply with regard to events set forth in Sec. 17 para. 1 which are equivalent to a direct listing at
a stock exchange. 

  

	4.	This Agreement shall apply to all shares held by the Parties and shall apply to current and future shareholdings in the Company. 

  
 - 33 / 42 - 

 Sec. 24 

Miscellaneous 
  

	1.	If this Agreement refers to a resolution or vote of the Shareholders or a specific group of Shareholders outside shareholders’ meetings, the following provisions shall apply: The request for such a resolution or
vote shall be made by any of such Shareholders in writing, by telefax and/or e-mail to all Shareholders who are part of the specific group. The resolution or vote shall be made within ten calendar days following the sending of the request and be
taken in writing, by telephone, telefax and/or e-mail. The resolution or vote shall be deemed taken if Shareholders representing the majority required for such resolution or vote agree to the proposed resolution or vote within this time limit
irrespective of whether all Shareholders of the specific group participate in the resolution or vote. Minutes of the resolution or vote shall be drawn up and shall be signed by the Shareholder requesting the resolution or vote immediately after the
passing of such resolution or vote, and a copy shall be provided to each Shareholder and the Company. 

  

	2.	The Company and the Shareholders herewith, in advance, grant their consent to employees and other persons who were granted an option to acquire shares in the Company and who exercise their respective options granted, to
enter into this Agreement, to the extent that such entering into this Agreement as party hereto is provided for by the terms of the Company’s stock option plan. In the event that the shares’ pro-rata participation in the share capital
should be adjusted or any capital increase from reserves (Kapitalerhöhung aus Gesellschaftsmitteln), the Euro-amounts (liquidation- and sale proceeds preference, compulsory conversion of preference shares into common shares pursuant to
Sec. 10 para. 3, anti-dilution protection), as the case may be, set forth in this Agreement and in the Company’s Articles of Association shall be adjusted accordingly. 

 

	3.	Prof. Dr. Arne Skerra undertakes that he will manage his shareholding in Prof. Skerra Beteiligungsgesellschaft mbH only in accordance with this Agreement and that Prof. Skerra Beteiligungsgesellschaft mbH will
dispose of and manage its shareholding in the Company only in accordance with this Agreement. The same is hereby undertaken by Dr. Martin Pöhlchen with regard to his shareholding in MAPO Beteiligungsgesellschaft mbH and the shareholding of
MAPO Beteiligungsgesellschaft in the Company. 

  
 - 34 / 42 - 

	4.	In the event that certain provisions set forth in this Agreement and those set forth in the Articles of Association of the Company should conflict or provide different terms and conditions in respect of an issue, the
terms and conditions set forth in this Agreement shall prevail over the contents of the Articles of Association, to the extent legally permissible. In the event of such different provisions or a conflict of clauses, the Shareholders shall, to the
extent legally permissible, amend the Articles of Association so that they conform with the terms and provisions set forth herein. 

  

	5.	The Parties are aware that the investment in the Company are in part refinanced by the KfW. KfW, in return for agreeing to effect such refinance, requires under certain circumstances that such investment refinanced by
KfW pro rata may be pledged. KfW’s terms and conditions also include the requirement that KfW, BMWi or their respective appointees pursuant to § 1 BHO (Bundeshaushaltsordnung) and the Bundesrechnungshof are granted the right to
supervise the way funds are granted are employed. In order to comply with such requirement, the aforementioned entities are entitled to inspect the Company’s books and records and to generally demand information about the Company’s
financial standing. The inspection and information rights as aforesaid may also be exercised / carried out by an auditor appointed by an Investor Majority. The costs for such auditor are to be borne by such requesting shareholder. 

 

	6.	The Parties consent that KfW is managing its shareholdings in the Company in accordance with the “Principles of Participations in Technology Companies” as attached hereto as Exhibit 24.6.

  

	7.	To the extent legally permissible, place of venue and performance shall be Munich, Germany. All disputes arising out of or in connection with this Agreement shall be finally settled in accordance with the Arbitration
Rules of the German Institution of Arbitration e.V. (DIS) without recourse to the ordinary courts of law and according to the Arbitration Agreement enclosed to the Investment Agreement. This shall include disputes regarding the validity, the
performance or the termination of this Agreement in whole or in part including possible amendments of the same. The place of arbitration is Munich, Germany. The arbitration tribunal consists of three arbitrators. The language of the arbitration
proceedings is English. 

  

	8.	Any amendments or alterations to this Agreement, including a waiver of the written form requirement, require to be in writing in order to be valid. 

  
 - 35 / 42 - 

	9.	In the event that a provision of this Agreement is or proves to be invalid or unenforceable, the validity of the remaining provisions hereof and the Investment Agreement shall not be affected thereby. The invalid or
unenforceable provision is moreover to be replaced by a valid and enforceable provision which reaches the Parties’ original commercial intent as at the date hereof to the closest possible extent. The foregoing shall also apply in the event of
contractual provisions that prove to be missing. 

  

	10.	This Agreement shall be governed by and construed in accordance with the laws of the Federal Republic of Germany without regard to the conflicts of laws provisions thereof and the CISG. 

 

	11.	The Company and the Preferred Shareholders shall commonly agree on the format and contents of a press release regarding the closing of this Agreement. 

Munich, October 10, 2014 
  

					
	 /s/ i.V. Th.
Strassner            /s/ Hans Küpper
	 		 	 /s/ i.V. Th. Strassner

	 Pieris AG

(represented by the management board and the supervisory board)
	 		 	Prof. Skerra Beteiligungsgesellschaft mbH
			
	 /s/ i.V. Th. Strassner
	 		 	 /s/ i.V. Th. Strassner

	Dr. Steffen Schlehuber	 		 	Claus Schalper
			
	 /s/ i.V. Th. Strassner
	 		 	 /s/ i.V. Th. Strassner

	Dr. Karsten Schürrle	 		 	MAPO Beteiligungsgesellschaft mbH
			
	 /s/ i.V. Th. Strassner
	 		 	 /s/ i.V. Th. Strassner

	BioM Aktiengesellschaft Munich BioTech Development	 		 	BioM Venture Capital GmbH & Co. Fonds KG
			
	 /s/ i.V. Th. Strassner
	 		 	 /s/ i.V. Th. Strassner

	TransConnect Unternehmensberatungs- und Beteiligungs AG	 		 	The Global Life Science Ventures Fonds II GmbH & Co. KG

  
 - 36 / 42 - 

					
			
	 /s/ i.V. Th. Strassner
	 		 	 /s/ i.V. Th. Strassner

	The Global Life Science Ventures Fund II Limited Partnership	 		 	Gilde Europe Food & Agribusiness Fund B.V.
			
	 /s/ i.V. Th. Strassner
	 		 	 /s/ i.V. Th. Strassner

	BayTech Venture Capital GmbH & Co. KG	 		 	Coöperatieve AAC LS U.A.
			
	 /s/ Jiang Bian
	 		 	 /s/ i.V. Th. Strassner

	KfW	 		 	Technologie Beteiligungsfonds Bayern II GmbH & Co. KG
			
	 /s/ i.V. Th. Strassner
	 		 	 /s/ i.V. Th. Strassner

	OrbiMed Private Investments III, LP	 		 	OrbiMed Associates III, LP
			
	 /s/ i.V. Th. Strassner
	 		 	 /s/ i.V. Th. Strassner

	Novo Nordisk A/S	 		 	Cadila Healthcare Ltd.
			
	 /s/ i.V. Th. Strassner
	 		 	 /s/ i.V. Th. Strassner

	Dr. Martin Pöhlchen	 		 	Prof. Dr. Arne Skerra

  
 - 37 / 42 - 

 Exhibits: 
  

					
	Exhibit A	 	-	  	List of Holders of Common Shares, of Preferred Shares Series A, of Preferred Shares Series A-1, of Preferred Shares Series B, of Preferred Shares Series C, of Indirect Shareholders and of Founders
			
	Exhibit 24.6	 	-	  	“Principles of Participations in Technology Companies” by KfW

  
 - 38 / 42 - 

 Exhibit A: 

List of Holders of Common Shares, of Preferred Shares Series A, of Preferred Shares Series A-1, of Preferred Shares Series B, of
Preferred Shares Series C, of Indirect Shareholders and of Founders 
  

			
	 Name
	  	 Participation as

	Prof. Skerra Beteiligungsgesellschaft mbH, Max-Lehner-Straße 19, 85354 Freising, Germany	  	 Holder of Common Shares
  

Founder

		
	Dr. Steffen Schlehuber, In den Kappesgärten 22, 67152 Ruppertsberg, Germany	  	 Holder of Common Shares
  

Founder

		
	Claus Schalper, Kaiser-Ludwig-Platz 1, 80336 Munich, Germany	  	 Holder of Common Shares
  

Founder

		
	Dr. Karsten Schürrle, Palmstraße 7, 60316 Frankfurt a.M., Germany	  	 Holder of Common Shares
  

Founder

		
	MAPO Beteiligungsgesellschaft mbH, Hubertusweg 34, 85540 Haar, Germany	  	Holder of Common Shares
		
	BioM Aktiengesellschaft Munich BioTech Development, Am Klopferspitz 19 a, 82152 Planegg-Martinsried, Germany	  	 Holder of Common Shares
  

Holder of Preferred Shares Series B
  

Holder of Preferred Shares Series C

		
	BioM Venture Capital GmbH & Co. Fonds KG, Am Klopferspitz 19 a, 82152 Planegg-Martinsried, Germany	  	 Holder of Common Shares
  

Holder of Preferred Shares Series A
  

Holder of Preferred Shares Series A-1
  

Holder of Preferred Shares Series B

		
	TransConnect Unternehmensberatungs- und Beteiligungs AG, Prinzregentenstraße 56, 80538 Munich, Germany	  	 Holder of Common Shares
  

Holder of Preferred Shares Series A
  

Holder of Preferred Shares Series A-1
  

Holder of Preferred Shares Series B
  

Holder of Preferred Shares Series C

  
 - 39 / 42 - 

			
	The Global Life Science Ventures Fonds II GmbH & Co. KG, Von-der-Tann-Straße 3, 80539 Munich, Germany	  	 Holder of Preferred Shares Series A
  

Holder of Preferred Shares Series A-1
  

Holder of Preferred Shares Series B
  

Holder of Preferred Shares Series C

		
	The Global Life Science Ventures Fund II Limited Partnership, PO Box 431, Alexander House,13-15 Victoria Road, St. Peter Port, Guernsey, G41 3ZD	  	 Holder of Preferred Shares Series A
  

Holder of Preferred Shares Series A-1
  

Holder of Preferred Shares Series B
  

Holder of Preferred Shares Series C

		
	Gilde Europe Food & Agribusiness Fund B.V., Newtonlaan 91, 3584 BP Utrecht, The Netherlands	  	 Holder of Preferred Shares Series A
  

Holder of Preferred Shares Series A-1
  

Holder of Preferred Shares Series B
  

Holder of Preferred Shares Series C

		
	BayTech Venture Capital GmbH & Co. KG, Herzog-Heinrich-Straße 22, D-80336 Munich, Germany	  	 Holder of Preferred Shares Series A
  

Holder of Preferred Shares Series A-1
  

Holder of Preferred Shares Series B
  

Holder of Preferred Shares Series C

		
	Coöperatieve AAC LS U.A., Gooimeer 2-35, P.O. Box 5187, 1410 AD Naarden, The Netherlands	  	 Holder of Preferred Shares Series A
  

Holder of Preferred Shares Series A-1
  

Holder of Preferred Shares Series B
  

Holder of Preferred Shares Series C

		
	KfW, Ludwig-Erhard-Platz 1-3, 53179 Bonn, Germany	  	 Holder of Preferred Shares Series A-1
  

Holder of Preferred Shares Series B

		
	Technologie Beteiligungsfonds Bayern II GmbH & Co. KG, Ländgasse 135a, 84028 Landshut, Germany	  	 Holder of Preferred Shares Series A-1
  

Holder of Preferred Shares Series B

		
	OrbiMed Private Investments III, LP, 601 Lexington Avenue, 54th Floor, New York, NY 10022, USA	  	 Holder of Preferred Shares Series B
  

Holder of Preferred Shares Series C

		
	OrbiMed Associates III, LP, 601 Lexington Avenue, 54th Floor, New York, NY 10022, USA	  	 Holder of Preferred Shares Series B
  

Holder of Preferred Shares Series C

  
 - 40 / 42 - 

			
	Novo Nordisk A/S, Novo Allé, 2880 Bagsværd, Denmark	  	 Holder of Preferred Shares Series B
  

Holder of Preferred Shares Series C

		
	Cadila Healthcare Ltd., Zydus Tower, Satellite Cross Roads, Ahmedabad - 380 015, India	  	Holder of Preferred Shares Series C
		
	Prof. Dr. Arne Skerra, Max-Lehner-Straße 19, 85354 Freising, Germany	  	Indirect Shareholder
		
	Dr. Martin Pöhlchen, Hubertusweg 34, 85540 Haar, Germany	  	Indirect Shareholder

  
 - 41 / 42 - 

 Exhibit 24.6: 

“Principles of Participations in Technology Companies” by KfW 

  
 - 42 / 42 -EX-10.31

 EXHIBIT 10.31 
  

 
 Execution Version 

Investment Agreement 

Pieris AG, Freising, Germany 

dated October 10, 2014 

by and among 
  

	1.	Pieris AG, whose principal place of business is at Lise-Meitner-Str. 30, 85354 Freising, Germany (the “Company”), represented by its management board, consisting of Stephen Yoder, and its supervisory
board, being represented by its chairman, Dr. Hans A. Küpper; 

  

	2.	Stephen Yoder, being the sole member of the management board of the Company; 

  

	3.	The persons listed in Exhibit A who are the existing shareholders in the Company (jointly “Existing Shareholders”); 

and 
  

	4.	The persons listed in Exhibit B who are the (i) future shareholders in the Company and (ii) Existing Shareholders investing in this financing round along with the future shareholders with regard to
their new preferred shares series C (jointly “Investors” or “Holders of Preferred Shares Series C”). 

 The
Existing Shareholders and the Investors shall jointly be referred to as the “Shareholders”. The Shareholders, the Company and Stephen Yoder shall jointly be referred to as the “Parties”. 

Preamble 
  

	A.	The Shareholders are the current and future shareholders of the Company, which is registered in the commercial register of the local court of Munich (hereinafter referred to as the “Commercial
Register”) under no. HRB 133223. The object of the Company is the biotechnological research and development and the distribution of applications of the research results. 

 

	B.	 With regard to the Company a series of rounds of financing providing for equity capital were closed and corresponding agreements were entered into, in
particular the Investment Agreement and the Shareholders Agreement both dated October 23, 2002, the Investment Agreement dated October 14, 2004 (file no. V 2519/2004 of the notary Dr. Oliver Vossius, Munich), the Investment
Agreement and the Shareholders Agreement both dated November 13, 

	 	
2006, the Investment Agreement and Consolidated Shareholders’ Agreement both dated March 26, 2008 as well as the Consolidated Shareholders’ Agreement 2012 dated November 12,
2012 (jointly the “Existing Agreements”). All Existing Agreements will be consolidated and replaced by a new consolidated shareholders’ agreement 2014 attached hereto as Exhibit C (the “CSA 2014”).

  

	C.	The Company’s share capital currently amounts to EUR 979,701.00 and is divided into 59,993 common shares, 324,313 preferred shares series A, 132,432 preferred shares series A-1 and 462,963 preferred shares
series B. All shares are non-par value shares with a portion of the Company’s share capital (anteiliger Betrag des Grundkapitals) of EUR 1.00 each, and are in registered form. 

 

	D.	The current shareholding is as follows: 

  

																	
	 Name of Existing Shareholder
	  	Number of
Common
Shares	 	  	Number
of Preferred
Shares
Series A	 	  	Number
of Preferred
Shares
Series A-1	 	  	Number
of Preferred
Shares
Series B	 
	 Prof. Skerra Beteiligungsgesellschaft mbH
	  	 	43.663	  	  				  				  			
	 Dr. Steffen Schlehuber
	  	 	1.162	  	  				  				  			
	 Claus Schalper
	  	 	870	  	  				  				  			
	 Dr. Karsten Schürrle
	  	 	584	  	  				  				  			
	 MAPO Beteiligungsgesellschaft mbH
	  	 	5.664	  	  				  				  			
	 BioM Aktiengesellschaft Munich BioTech Development
	  	 	2.950	  	  				  				  	 	1.852	  
	 BioM Venture Capital GmbH & Co. Fonds KG
	  	 	1.870	  	  	 	40.537	  	  	 	8.277	  	  	 	5.926	  
	 TransConnect Unternehmensberatungs- und Beteiligungs AG
	  	 	3.230	  	  	 	6.755	  	  	 	2.570	  	  	 	6.189	  
	 The Global Life Science Ventures Fonds II GmbH & Co. KG
	  				  	 	45.606	  	  	 	17.358	  	  	 	31.035	  
	 The Global Life Science Ventures Fund II LP
	  				  	 	35.474	  	  	 	13.501	  	  	 	24.139	  
	 Gilde Europe Food & Agribusiness Fund B.V.
	  				  	 	81.080	  	  	 	30.858	  	  	 	55.174	  
	 BayTech Venture Capital GmbH & Co. KG
	  				  	 	60.812	  	  	 	9.312	  	  	 	9.312	  
	 Coöperatieve AAC LS U.A.
	  				  	 	54.049	  	  	 	14.070	  	  	 	33.575	  
	 KfW
	  				  				  	 	22.973	  	  	 	11.324	  
	 Technologie Beteiligungsfonds Bayern II GmbH & Co. KG
	  				  				  	 	13.513	  	  	 	6.659	  
	 OrbiMed Private Investments III, LP
	  				  				  				  	 	183.438	  
	 OrbiMed Associates III, LP
	  				  				  				  	 	1.747	  
	 Novo Nordisk A/S
	  				  				  				  	 	92.593	  
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 Total
	  	 	59.993	  	  	 	324.313	  	  	 	132.432	  	  	 	462.963	  
	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	  	 	979.701	  
		  	  
	  
	 

 TransConnect Unternehmensberatungs- und Beteiligungs AG became a shareholder in the Company by way of merger
(Verschmelzung) with the former shareholder TransConnect Corporate Finance Beratungs GmbH taking 

  
 - 2 / 35 - 

 
over all of its rights and duties as a shareholder in the Company in accordance with a merger agreement dated July 25, 2014, registered with the competent commercial register of TransConnect
Unternehmensberatungs- und Beteiligungs AG on September 11, 2014. 
  

	E.	On November 12, 2012, as amended in March 2014, and on April 14, 2014, the Company and the Existing Shareholders entered into agreements regarding convertible bridge loans (Wandeldarlehen) (jointly the
“Loan Agreements”) totaling to a loan amount of EUR 4,000,000.00 (the “Convertible Loans”). The lending Existing Shareholders (jointly the “Lending Shareholders”) have provided to the Company
loan facilities under the Convertible Loans, which are currently outstanding as follows: 

  

									
	 Lending Shareholder
	  	Advanced Loan
Amount 2012
in EUR	 	  	Advanced Loan
Amount 2014
in EUR	 
	 OrbiMed Private Investments III, LP
	  	 	492.113	  	  	 	797.987	  
	 OrbiMed Associates III, LP
	  	 	4.687	  	  	 	5.001	  
	 Novo Nordisk A/S
	  	 	199.606	  	  	 	199.606	  
	 TransConnect Unternehmensberatungs- und Beteiligungs AG
	  	 	50.285	  	  	 	53.659	  
	 BioM Aktiengesellschaft Munich BioTech Development
	  	 	164.751	  	  	 	13.747	  
	 The Global Life Science Ventures Fonds II GmbH & Co. KG
	  	 	252.173	  	  	 	168.746	  
	 The Global Life Science Ventures Fund II LP
	  	 	196.145	  	  	 	131.254	  
	 Gilde Europe Food & Agribusiness Fund B.V.
	  	 	421.015	  	  	 	300.000	  
	 BayTech Venture Capital GmbH & Co. KG
	  	 	0	  	  	 	200.000	  
	 Coöperatieve AAC LS U.A.
	  	 	219.225	  	  	 	130.000	  
		  	  
	  
	 	  	  
	  
	 
	 Total
	  	 	2.000.000	  	  	 	2.000.000	  
	  	  
	  
	 	  	  
	  
	 
	  	 	4.000.000	  
		  	  
	  
	 

 In the course of this financing round (the “2014 Financing Round”) the Lending Shareholders
will convert the Convertible Loans into new preferred shares series C of the Company by way of contribution of the respective claim for repayment of the outstanding loan facilities (the “Repayment Claims”) into the capital reserves
of the Company. 

  
 - 3 / 35 - 

	F.	The Company seeks further growth financing amounting to a total of up to EUR 4,970,149.15 in new money (equaling USD 6,660,000; not taking into account the Convertible Loans) in the 2014 Financing Round, which
is divided into two tranches, by the issuance of new preferred shares series C. The Investors are prepared to commit the first tranche in the amount of EUR 3,552,646.44 (equaling USD 4,760,546.23) as additional equity capital under the
terms of this investment agreement (“Investment Agreement”) as follows: 

  

					
	 Investor
	  	Total Investment in EUR	 
	 OrbiMed Private Investments III, LP
	  	 	1.819.978,03	  
	 OrbiMed Associates III, LP
	  	 	17.333,90	  
	 Cadila Healthcare Ltd. (“Zydus”)
	  	 	1.492.537,31	  
	 TransConnect Unternehmensberatungs- und Beteiligungs AG
	  	 	47.797,20	  
	 BayTech Venture Capital GmbH & Co. KG
	  	 	175.000,00	  
		  	  
	  
	 
	 Total
	  	 	3.552.646,44	  
		  	  
	  
	 

 As part of the first tranche of the 2014 Financing Round, OrbiMed Private Investments III, LP will pay the
aggregate amount of the total issue price of the new shares to be issued to the Lending Shareholders Novo Nordisk A/S, BioM Aktiengesellschaft Munich BioTech Development, The Global Life Science Ventures Fonds II GmbH & Co. KG, The Global
Life Science Ventures Fund II LP, Gilde Europe Food & Agribusiness Fund B.V. and Coöperatieve AAC LS U.A. (jointly the “Lenders”) for the contribution of the respective Repayment Claims on behalf of and to the benefit
of the Lenders in exchange for these Lenders contributing a corresponding portion of the Repayment Claims into the capital reserves of the Company on behalf of and to the benefit of OrbiMed Private Investments III, LP. 

 

	G.	A new authorized capital 2014 (Genehmigtes Kapital 2014) will be created for the second tranche of the 2014 Financing Round amounting to up to EUR 1,417,502.71 (equaling USD 1,899,454) as additional
equity capital and the management board with the approval of the supervisory board of the Company shall be authorized to invite Shareholders and/or new investors to subscribe for new preferred shares series C to be issued in this second tranche.

  

	H.	 The Parties intend to regulate their relationship as current and future shareholders of the Company by entering into a separate shareholders’
agreement, the CSA 2014. The CSA 2014 shall form an integral part of this Investment Agreement. Capitalized terms used but not defined herein shall 

  
 - 4 / 35 - 

	 	
have the same meaning as given to them in the CSA 2014. Upon this Investment Agreement and the CSA 2014 coming into force, all prior agreements between the undersigning parties regulating their
relationship as shareholders of the Company, including but not limited to the Existing Agreements and the Loan Agreements, shall be terminated and finally superseded, except for the cooperation agreements of the Company currently in effect with
(i) KfW or Technologie Beteiligungsfonds Bayern II GmbH & Co. KG respectively and (ii) The Global Life Science Ventures Fonds II GmbH & Co. KG and The Global Life Science Ventures Fund II Limited Partnership,
respectively. 

  

	I.	It is the common intention of the Shareholders that the shares of the Company are listed on a stock exchange or the Company is sold to a third party in due course. 

NOW, THEREFORE, the Parties hereby enter into the following Investment Agreement: 

Sec. 1 
 First Tranche
Capital Increase 
  

	1.	The Existing Shareholders shall resolve unanimously and with the votes of all Existing Shareholders in a shareholders’ meeting to be held in the form of a plenary meeting (Vollversammlung) immediately after
the signing of this Investment Agreement and the CSA 2014 (the “Shareholders’ Meeting”) to increase the share capital of the Company from EUR 979,701.00 by EUR 1,629,469.00 to EUR 2,609,170.00 in return for
cash contributions by the issuance of 1,629,469 new preferred shares series C (the “First Tranche”), each in registered form, which shall be issued as non-par value shares with a portion of the Company’s share capital
(anteiliger Betrag des Grundkapitals) of EUR 1.00 each, and to restate the articles of association (Satzung) of the Company, a draft of the restated articles of association is attached hereto as Exhibit 1.1. The new shares
shall be issued for the amount of EUR 1.00 per new share (total issue price). The new shares shall have the right to participate in profits as from January 1, 2014. The new preferred shares series C shall have the rights, preferences and
privileges as set forth in the restated articles of association attached hereto as Exhibit 1.1. 

  
 - 5 / 35 - 

	2.	To the exclusion of the Existing Shareholders’ subscription rights, the Investors shall be invited and obliged to subscribe for the new preferred shares series C under this Sec. 1 as follows: 

 

					
	 Investor
	  	Preferred Shares Series C
(number)	 
	 OrbiMed Private Investments III, LP
	  	 	621.577	  
	 OrbiMed Associates III, LP
	  	 	5.375	  
	 Zydus
	  	 	247.310	  
	 Novo Nordisk A/S
	  	 	103.296	  
	 TransConnect Unternehmensberatungs- und Beteiligungs AG
	  	 	34.860	  
	 BioM Aktiengesellschaft Munich BioTech Development
	  	 	55.625	  
	 The Global Life Science Ventures Fonds II GmbH & Co. KG
	  	 	114.060	  
	 The Global Life Science Ventures Fund II LP
	  	 	88.717	  
	 Gilde Europe Food & Agribusiness Fund B.V.
	  	 	194.028	  
	 BayTech Venture Capital GmbH & Co. KG
	  	 	68.755	  
	 Coöperatieve AAC LS U.A.
	  	 	95.866	  
		  	  
	  
	 
	 Total
	  	 	1.629.469	  
		  	  
	  
	 

  

	3.	Each of the Shareholders undertakes individually for himself vis-à-vis each other Shareholder, to do or cause to be done everything necessary or appropriate to implement the measures agreed in this Sec. 1. Thus,
the Existing Shareholders undertake in particular to co-operate in the increase of the share capital and the restatement of the articles of association as described by exercising their voting rights in the Shareholders’ Meeting and in the
special resolutions of the different classes of shares accordingly and to waive the subscription rights to which they are entitled for the subscription to new preferred shares series C to the extent described. 

 

	4.	Each of the Holders of Preferred Shares Series C undertakes individually for himself vis-à-vis each of the Shareholders, to subscribe and to take over the new preferred shares series C to the extent as stated for
him in the table in Sec. 1 para. 2 above immediately after the end of the Shareholders’ Meeting and to pay in full and in cash the respective aggregate amount of the total issue price of EUR 1.00 per newly issued preferred share series C
subscribed by them under Sec. 1 para. 2 above, respectively, within ten bank working days in Frankfurt/Main, Germany after such Holder of Preferred Shares Series C has subscribed for the new preferred shares series C; provided, however,
that OrbiMed Private Investments III, LP undertakes vis-à-vis the Lenders to pay in time the following amounts on account of the aggregate amount of the total issue price of EUR 1.00 per newly issued preferred share series C to be issued
to and subscribed for and taken over by the Lenders under para. 2 above (Tilgungsbestimmung gem. § 267 BGB): 

  

					
	 Payment on behalf of and to the benefit of (Name of Lender)
	  	Aggregate Amount of the
Total Issue Price in EUR	 
	 Novo Nordisk A/S
	  	 	103.296	  
	 BioM Aktiengesellschaft Munich BioTech Development
	  	 	55.625	  
	 The Global Life Science Ventures Fonds II GmbH & Co. KG
	  	 	114.060	  
	 The Global Life Science Ventures Fund II LP
	  	 	88.717	  
	 Gilde Europe Food & Agribusiness Fund B.V.
	  	 	194.028	  
	 Coöperatieve AAC LS U.A.
	  	 	95.866	  
		  	  
	  
	 
	 Total
	  	 	651.592	  
		  	  
	  
	 

  
 - 6 / 35 - 

	5.	Payments on the total issue price of EUR 1.00 per newly issued preferred share series C shall be made exclusively to the following special account of the Company for the increase of the share capital (the
“Special Account”): 

  

			
	Account Holder:	  	Pieris AG
	Bank:	  	Deutsche Bank München
	IBAN:	  	DE82 7007 0010 0210 4248 01
	BIC:	  	DEUTDEMMXXX
	Reference:	  	Share Capital / First Tranche

 The Special Account will be opened solely for this purpose and must not be used for other transactions or
payments prior to the aforementioned payments. The Special Account must not have a debit balance immediately prior to the aforementioned payments being effected, so that the Company’s management board can freely dispose of the amounts paid (cf.
§§ 188, 36, 36a, 37 German Stock Corporation Act, AktG). 
  

	6.	The subscriptions shall become non-binding if the consummation (Durchführung) of the First Tranche has not been registered in the Commercial Register on or before six months after the Shareholders’
Meeting, in which case the Investors shall have the (additional) right to request the renewal of the First Tranche and the subscription. After subscription and taking over of the new preferred shares series C as described in this Sec. 1 and
receipt of the total issue price under this Sec. 1 from the Investors, the Company shall without undue delay (unverzüglich) apply for registration of the First Tranche and its consummation as well as the restated articles of association
with the Commercial Register and shall take all actions and make all declarations necessary or appropriate for the First Tranche and the restated articles of association to become effective. 

  
 - 7 / 35 - 

	7.	After the First Tranche has become effective to the full extent, the share capital of the Company will be held by the Shareholders as follows: 

 

																					
	 Name of Shareholder
	  	Number
of Common
Shares	 	  	Number
of Preferred
Shares
Series A	 	  	Number of
Preferred
Shares
Series A-1	 	  	Number of
Preferred
Shares
Series B	 	  	Number
of Preferred
Shares
Series C	 
	 Prof. Skerra Beteiligungsgesellschaft mbH
	  	 	43.663	  	  				  				  				  			
	 Dr. Steffen Schlehuber
	  	 	1.162	  	  				  				  				  			
	 Claus Schalper
	  	 	870	  	  				  				  				  			
	 Dr. Karsten Schürrle
	  	 	584	  	  				  				  				  			
	 MAPO Beteiligungsgesellschaft mbH
	  	 	5.664	  	  				  				  				  			
	 BioM Aktiengesellschaft Munich BioTech Development
	  	 	2.950	  	  				  				  	 	1.852	  	  	 	55.625	  
	 BioM Venture Capital GmbH & Co. Fonds KG
	  	 	1.870	  	  	 	40.537	  	  	 	8.277	  	  	 	5.926	  	  			
	 TransConnect Unternehmensberatungs- und Beteiligungs AG
	  	 	3.230	  	  	 	6.755	  	  	 	2.570	  	  	 	6.189	  	  	 	34.860	  
	 The Global Life Science Ventures Fonds II GmbH & Co. KG
	  				  	 	45.606	  	  	 	17.358	  	  	 	31.035	  	  	 	114.060	  
	 The Global Life Science Ventures Fund II LP
	  				  	 	35.474	  	  	 	13.501	  	  	 	24.139	  	  	 	88.717	  
	 Gilde Europe Food & Agribusiness Fund B.V.
	  				  	 	81.080	  	  	 	30.858	  	  	 	55.174	  	  	 	194.028	  
	 BayTech Venture Capital GmbH & Co. KG
	  				  	 	60.812	  	  	 	9.312	  	  	 	9.312	  	  	 	68.755	  
	 Coöperatieve AAC LS U.A.
	  				  	 	54.049	  	  	 	14.070	  	  	 	33.575	  	  	 	95.866	  
	 KfW
	  				  				  	 	22.973	  	  	 	11.324	  	  			
	 Technologie Beteiligungsfonds Bayern II GmbH & Co. KG
	  				  				  	 	13.513	  	  	 	6.659	  	  			
	 OrbiMed Private Investments III, LP
	  				  				  				  	 	183.438	  	  	 	621.577	  
	 OrbiMed Associates III, LP
	  				  				  				  	 	1.747	  	  	 	5.375	  
	 Novo Nordisk A/S
	  				  				  				  	 	92.593	  	  	 	103.296	  
	 Zydus
	  				  				  				  				  	 	247.310	  
	 Totals
	  	 	59.993	  	  	 	324.313	  	  	 	132.432	  	  	 	462.963	  	  	 	1.629.469	  
	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	  	 	2.609.170	  
		  	  
	  
	 

  

	8.	 The Shareholders undertake, as amongst each other, as from the conclusion of this Investment Agreement and until the increase of the share capital
under this Sec. 1 and the restated articles of association come into force and effect – to the extent that statutory provisions permit – to treat each other as if the restated articles of association had already come into force and effect
on the conclusion of this Investment Agreement and the Investors had already acquired the new shares under Sec. 1 para. 2 above upon subscription, respectively. Thus, each of the Shareholders undertakes individually for himself vis-à-vis each
of the Investors, as from the conclusion of this Investment 

  
 - 8 / 35 - 

	 	
Agreement, to put the Investors internally in such position as they each would be in, if they had acquired the financial rights (Vermögensrechte) and, to the extent legally
permissible, the administrative rights (Verwaltungsrechte) under this Investment Agreement, the CSA 2014 and the restated articles of association resulting from the new shares under Sec. 1 para. 2 above upon subscription,
respectively. Should the Commercial Register make valid objections to the increase of the share capital or the restatement of the articles of association, the Shareholders undertake, as amongst each other, to remove such objections without undue
delay by way of adopting the necessary resolutions in one or more shareholders’ meetings of the Company to be held as soon as possible so that the purpose and intention of the provisions objected to can be achieved to the maximum permissible
extent. 

  

	9.	In the Shareholders’ Meeting under Sec. 1 para. 1 above, the Existing Shareholders shall elect 

  

	 	a.	Mr. Chau Q. Khuong, as nominated by OrbiMed Private Investments III, LP pursuant to Sec. 16 para. 2 lit. a. of the CSA 2014; 

 

	 	b.	Mrs. Christina Takke, as jointly nominated by the holders of Preferred Shares Series B, Preferred Shares Series A-1 and Preferred Shares Series A pursuant to Sec. 16 para. 2 lit. b. of the CSA 2014; and

  

	 	c.	Michael Richman, as nominated by all Shareholders pursuant to Sec. 16 para. 2 lit. c. of the CSA 2014 

as members of the supervisory board for a term ending as of the end of the shareholders’ meeting resolving on the approval of the actions
(Entlastung) of the supervisory board for the business year 2015 with effect as of the end of the Shareholders’ Meeting under Sec. 1 para. 1 above. 

In the Shareholders’ Meeting under Sec. 1 para. 1 above, the Existing Shareholders shall furthermore terminate the appointment
of 
  

	 	a.	Dr. Hans A. Küpper; 

  

	 	b.	Mr. Michael B. Sheffery; 

  

	 	c.	Prof. Arne Skerra; and 

  

	 	d.	Edwin de Graaf 

 as members of the supervisory board with effect as of the end of the
Shareholders’ Meeting under Sec. 1 para. 1 above, unless the respective member of the supervisory board has submitted his resignation from office with same effect prior to such Shareholders’ Meeting. 

  
 - 9 / 35 - 

	10.	The Parties are in agreement that no rights to anti-dilution protection under Sec. 1 of the Consolidated Shareholders’ Agreement 2012 dated November 12, 2012 shall exist with respect to the 2014 Financing
Round. Each of the Preferred Shareholders hereby waives any and all rights to anti-dilution protection it might have under Sec. 1 of the Consolidated Shareholders’ Agreement 2012 dated November 12, 2012 with respect to the 2014
Financing Round; each of such waivers is hereby accepted by each of the other Parties. 

 Sec. 2 

Second Tranche Capital Increase / Authorized Capital 
  

	1.	In the Shareholders’ Meeting, the Existing Shareholders shall resolve unanimously and with the votes of all Existing Shareholders to authorize the management board of the Company to increase the share capital of
the Company up until June 30, 2015 with the consent of the supervisory board by up to EUR 234,877.00 in return for cash contributions by the issuance of up to further 234,877 new preferred shares series C (“Second
Tranche”), each in registered form, which shall be issued as non-par value shares with a portion of the Company’s share capital (anteiliger Betrag des Grundkapitals) of EUR 1.00 each (“Authorized Capital”).
The further preferred shares series C shall be issued for the amount of EUR 1.00 per new share (total issue price). The further preferred shares series C shall have the right to participate in profits as from the beginning of the year of their
issuance. The further preferred shares series C under this Sec. 2 shall have the same preferential rights as the preferred shares series C under Sec. 1 above. The statutory subscription rights of the shareholders of the Company shall be
excluded. The Authorized Capital shall only be used for the purpose provided in this Sec. 2. 

  

	2.	The management board with the consent of the supervisory board shall in particular be entitled (i) to invite in its free discretion one or more persons, including Shareholders and/or third parties,
(“Subsequent Investors”) to subscribe for and to take over all or part of the further preferred shares series C by way of utilizing the Authorized Capital and (ii) to exclude the statutory subscription rights of the
shareholders of the Company to the extent necessary for the grant of the subscription rights to such Subsequent Investors. 

  

	3.	 Subsequent Investors, who are not already party to this Investment Agreement, are required to accede (beitreten) to (i) this Investment
Agreement and the CSA 2014, substantially in the form of the joinder commitment attached 

  
 - 10 / 35 - 

	 	
hereto as Exhibit 2.3-1, and (ii) the Arbitration Agreement thereto, substantially in the form of the joinder commitment attached hereto as Exhibit 2.3-2, (jointly
“Joinder”) before being entitled to participate in the Second Tranche. The Joinder shall (i) ensure that each of the Subsequent Investors has the rights and duties of an Investor, a Holder of Preferred Shares Series C, a
Preferred Shareholder, a Shareholder and a Party under this Investment Agreement and the CSA 2014 and (ii) specify the number of new preferred shares series C to be subscribed for by the respective Subsequent Investor. Subsequent Investors who
are already party to this Investment Agreement shall specify the number of new preferred shares series C they wish to subscribe for pursuant to this Sec. 2 by way of a subscription statement, substantially in the form as attached hereto as
Exhibit 2.3-3 (“Subscription Declaration”). The respective Joinder or Subscription Declaration must be submitted to the Company no later than March 31, 2015, whereby the relevant time shall be the receipt by the Company.

  

	4.	Each of the Parties hereby expressly consents to, and hereby offers, the accession of the Subsequent Investors to this Investment Agreement, the CSA 2014 and the Arbitration Agreement and waives the requirement of being
notified of such accession (Verzicht auf den Zugang der Beitrittserklärung gemäß § 151 Satz 1 BGB). 

  

	5.	Regarding such capital increase out of the Authorized Capital, each of the Subsequent Investors undertakes individually for himself vis-à-vis each of the Shareholders upon submission of his Joinder or
Subscription Declaration, respectively, to subscribe and to take over the new preferred shares series C to the extent as stated in his Joinder or Subscription Declaration and to pay in full and in cash the respective aggregate amount of the total
issue price of EUR 1.00 per newly issued preferred share series C subscribed by them out of the Authorized Capital, respectively, within ten bank working days in Frankfurt/Main, Germany after subscription, to a special account of the Company
for the increase of capital named by the Company. Payments shall be made exclusively to this special account. The subscriptions shall only become non-binding, if the consummation (Durchführung) of the share capital increase has not been
registered in the Commercial Register within six months after the date of the resolution of the management board to utilize the Authorized Capital, in which case the Subsequent Investors shall have the (additional) right to request the renewal of
the increase of share capital and the subscription. The Company will pass the necessary resolutions based on the conditions provided herein. 

  

	6.	 Each of the Shareholders undertakes individually for himself vis-à-vis each other Shareholder, to do or cause to be done everything necessary
or appropriate to implement the measures agreed in this Sec. 2. In particular, the 

  
 - 11 / 35 - 

	 	
Shareholders hereby already and irrevocably (i) transfer all their rights for the subscription of further preferred shares series C according to this Sec. 2 to which they are entitled
to and (ii) waive any and all potential anti-dilution and subscription rights they might have according to law, the articles of association or the CSA 2014 with regard to the issuance of further preferred shares series C according to this
Sec. 2. Such waivers are hereby accepted by the respective other Parties. 

  

	7.	The management board shall be authorized to determine the further details of the share capital increase pursuant to this Sec. 2 and its consummation with the consent of the supervisory board. The supervisory board shall
be authorized to amend the version of the articles of association of the Company after the full or partial consummation of the share capital increase under this Sec. 2 and/or the expiry of the authorization accordingly. 

Sec. 3 
 Non-Statutory
Payments and Contributions to the Capital Reserves; Call Option 
  

	1.	Subject to the deductions provided for in Sec. 6 para. 2 below, the Holders of Preferred Shares Series C undertake individually for themselves vis-à-vis each of the Shareholders, but not
vis-à-vis the Company, to render, in addition to the aggregate amount of the total issue price of EUR 1.00 for each new preferred share series C subscribed by them in the First Tranche under Sec. 1 above, respectively, further
payments and contributions into the capital reserves of the Company pursuant to § 272 para. 2 no. 4 German Commercial Code (“HGB”) as follows: 

 

	 	a.	 Subject to the deductions provided for in Sec. 6 para. 2 below, OrbiMed Private Investments III, LP shall make cash payments in the amount
of EUR 1,198,402; provided, however, that OrbiMed Private Investments III, LP shall be entitled to deduct the amounts paid by it on account of the aggregate amount of the total issue price of EUR 1.00 per newly issued preferred share
series C to be issued to and subscribed for and taken over by the Lenders pursuant to Sec. 1 para. 4 above from the further payments into the capital reserves of the Company under this Sec. 3. Irrespective of such deduction, any amounts
deducted from the further payments into the capital reserves of the Company under the preceding sentence shall be treated as fully rendered by OrbiMed Private Investments III, LP to the Company for all purposes of this Investment Agreement and the
CSA 2014. For the avoidance of doubt: After full payment of the amounts 

  
 - 12 / 35 - 

	 	
to be paid by OrbiMed Private Investments III, LP on account of the aggregate amount of the total issue price of EUR 1.00 per newly issued preferred share series C to be issued to and
subscribed for and taken over by the Lenders pursuant to Sec. 1 para. 4 above, the remainder to be rendered to the capital reserves under this lit. a. amounts to EUR 546,810; 

 

	 	b.	Subject to the deductions provided for in Sec. 6 para. 2 below, OrbiMed Associates III, LP shall make cash payments in the amount of EUR 11,958; 

 

	 	c.	Zydus shall make cash payments in the amount of EUR 1,245,227; 

  

	 	d.	TransConnect Unternehmensberatungs- und Beteiligungs AG shall make cash payments in the amount of EUR 12,937; 

  

	 	e.	BayTech Venture Capital GmbH & Co. KG shall make cash payments in the amount of EUR 106,245; 

  

	 	f.	Each of the Lending Shareholders shall assign to the Company its Repayment Claims (including, for the avoidance of doubt, any and all interest accrued on the corresponding Convertible Loans) and shall waive
vis-à-vis the Company any and all claims out of or in connection with the Loan Agreements and the corresponding Convertible Loans, it being understood that a portion of such assignments by the Lenders, in each case equal to the amount set
forth in the table in Sec. 1 para. 4 above, shall be rendered by the Lenders on behalf of and to the benefit of OrbiMed Private Investments III, LP. 

  

	2.	The cash payments into the capital reserves of the Company pursuant to para. 1 lit. a. to lit. e. above shall become due for payment in full to the Special Account within ten bank working days in Frankfurt am
Main, Germany after the consummation of the First Tranche and the restated articles of association under Sec. 1 para. 1 above have been registered in the Commercial Register and a corresponding receipt of a notification from the Company in
writing, by telefax or e-mail, provided (i) that no insolvency proceedings have been commenced with respect to the Company and/or its assets and that no indisputable application to commence insolvency proceedings is pending, (ii) the
payment of Zydus pursuant to para. 1 lit. c. shall not become due until allotment of an unique identification number (“UIN”) by the competent authority in India or the lapse of such requirement, and (iii) by way of a condition
precedent (aufschiebende Bedingung) that the cash payments into the capital reserves of the Company pursuant to para. 1 lit. a. to lit. e. above shall become due for payment only after the passing of the resolutions of the
Shareholders’ Meeting set forth in Sec. 1 para. 9 and Sec. 2 paras. 1, 2 and 7 above. Zydus shall use its reasonable best efforts to achieve the allotment of the UIN as soon as practicable and shall inform the Company
thereof without undue delay. 

  
 - 13 / 35 - 

	3.	The assignments to the Company and the waivers vis-à-vis the Company pursuant to para. 1 lit. f. above shall become due in full within ten bank working days in Frankfurt am Main, Germany after receipt
of a notification from the Company in writing, by telefax or e-mail that the Company has received the cash payments into the capital reserves of the Company pursuant to para. 1 lit. a. to lit. e. above. 

 

	4.	Each of the Lenders severally not jointly (teilschuldnerisch) shall indemnify, defend and hold harmless (freistellen) OrbiMed Private Investments III, LP from and against any losses, claims, damages,
demands, actions, taxes, liabilities or expenses arising as a result of OrbiMed Private Investments III, LP paying the amounts set forth in Sec. 1 para. 4 above on account of the aggregate amount of the total issue price of EUR 1.00
per newly issued preferred share series C to be issued to and subscribed for and taken over by the Lenders under Sec. 1 para. 2 above on behalf of and to the benefit of the Lenders. 

 

	5.	Each of the Subsequent Investors undertakes individually for himself vis-à-vis each Shareholder, but not vis-à-vis the Company, to render, in addition to the aggregate amount of the total issue price of
EUR 1.00 for each new preferred share series C subscribed by him in the Second Tranche under Sec. 2 above, further payments into the capital reserves of the Company pursuant to § 272 para. 2 no. 4 German Commercial Code (HGB)
in cash in the amount of EUR 5.0373 (equal to USD 6.75) per share subscribed by him in the Second Tranche. These further payments into the capital reserves of the Company shall become due for payment in full to the Special Account within ten
bank working days in Frankfurt/Main, Germany after receipt of a notification by the respective Subsequent Investor from the Company in writing, by telefax or e-mail that the consummation of the respective portion of the Second Tranche has been
registered in the Commercial Register. 

  

	6.	The obligations of the Investors, Lending Shareholders and Subsequent Investors to render further payments and contributions into the capital reserves of the Company pursuant to this Sec. 3 shall exist only on the basis
of a contractual agreement among the Shareholders and the Investors, Lending Shareholders and Subsequent Investors, but not vis-à-vis the Company. The Company itself shall not be a party to this Sec. 3 and shall not be entitled to demand the
payments and contributions pursuant to this Sec. 3. This Sec. 3 shall not constitute an agreement in favour of third parties (kein Vertrag zugunsten Dritter). The claims under this Sec. 3 cannot be assigned. 

 

	7.	 Zydus hereby irrevocably offers the other Shareholders to transfer and assign for free, i.e. without consideration, 83.43 % of the new preferred
shares 

  
 - 14 / 35 - 

	 	
series C subscribed for by it pursuant to Sec. 1 para. 2, i.e. 206,331 new preferred shares series C (“Option Shares”) to such other Shareholders on a pro rata
basis (“Offer”). Acceptance of the Offer by the respective Shareholders shall be possible only if Zydus (i) does not receive the UIN and (ii) does not render the payments into the capital reserves of the Company pursuant
to para. 1 lit. c. within six (6) months following the date of this Agreement (“Longstop Period”); the Longstop Period can be extended with the approval of the Investor Majority. Acceptance of the Offer must be made
in writing to Zydus by the other Shareholders and shall always only be effective in the number of Option Shares to which the respective Shareholder is entitled to. Zydus and the other Shareholders hereby agree to the assignment (Abtretung) of
the Option Shares the transfer of which has been accepted in accordance with this para. 7. Following acceptance of the Offer the Option Shares shall be converted to common shares of the Company. 

Sec. 4 
 Use of Proceeds

 The proceeds from the 2014 Financing Round shall be used to fund working capital needs, capital expenditures and general corporate
purposes of the Company in accordance with the then-current budget of the Company, as adapted and modified with the approval of the supervisory board from time to time. 

Sec. 5 
 Representations
and Warranties 
  

	1.	Stephen Yoder in his capacity as member of the management board of the Company gives, within the meaning and with the legal consequences set forth in this Sec. 5, unless otherwise stated regardless of fault or
negligence (ohne Rücksicht auf Verschulden), the representations and warranties which are in detail included in Exhibit 5.1 to this Investment Agreement, subject to the provisions of this Sec. 5, to each of the Holders of
Preferred Shares Series C. 

  

	2.	 The representations and warranties within the meaning of this Investment Agreement and Exhibit 5.1 hereto and the right to demand damages
in relation thereto constitute a special agreement negotiated and agreed upon between the Parties specifically for the purposes of this 2014 Financing Round in accordance with § 311 para. 1 German Civil Code (BGB); accordingly,
unless 

  
 - 15 / 35 - 

	 	
otherwise stated, claims for damages under this Sec. 5 do not require intent or negligence (Vorsatz oder Fahrlässigkeit) of Stephen Yoder. Further, the representations and
warranties within the meaning of this Investment Agreement and Exhibit 5.1 hereto are subject to all the limitations set forth in this Investment Agreement and Exhibit 5.1 hereto, in particular, any limitation set forth in
the respective statement contained in Exhibit 5.1 hereto and the limitations on damages set forth in this Sec. 5. The Parties agree that none of the representations and warranties contained in this Investment Agreement and
Exhibit 5.1 hereto constitutes a guarantee with respect to the quality of the object of sale (Garantie für die Beschaffenheit der Sache) within the meaning of § 443 and § 444, 2nd alternative BGB. The legal consequences of a possible violation of the representations and warranties shall be determined exclusively pursuant to this Sec. 5. The Parties further agree that the
provisions of §§ 434 through 453 BGB relating to defects in quality or in title shall not apply to any representation or warranty contained in this Investment Agreement or Exhibit 5.1 hereto. §§ 377 et seq. HGB
shall not apply. 

  

	3.	 In the event that the representations and warranties set forth in Exhibit 5.1 hereto are not fully true and correct, then the Shareholders
to the exclusion of other remedies shall resolve in favor of an increase of the Company’s share capital (hereinafter referred to as the “Compensatory Share Capital Increase”) upon the demand of one or more of the Holders of
Preferred Shares Series C. The Compensatory Share Capital Increase shall be resolved and completed without undue delay after the demand by any of the Holders of Preferred Shares Series C. Each of the Holders of Preferred Shares Series C individually
may request his participation in the Compensatory Share Capital Increase without being obliged to do so. As part of the Compensatory Share Capital Increase, the Holders of Preferred Shares Series C, who request this, shall be invited, to the
exclusion of the other Shareholders’ subscription rights, to subscribe to additional preferred shares series C in return for cash contributions at the portion of the Company’s share capital attributable to one share (anteiliger Betrag
des Grundkapitals) without premium or other contributions into the capital reserves of the Company, by means of which the Holders of Preferred Shares Series C shall receive such participation in the Company’s share capital as they each
would have held, if they had invested the funds committed under this Investment Agreement (including, for the avoidance of doubt, the respective Repayment Claims) and the additional funds provided in the Compensatory Share Capital Increase from the
start at the Reduced Valuation (as defined below), thereby applying a discount on the Reduced Valuation with respect to the conversion of the Convertible Loans as provided in the Loan Agreements. The “Reduced Valuation” shall be
equal to a pre-money valuation of the Company 

  
 - 16 / 35 - 

	 	
fully-diluted of EUR 11,194,029 (equaling USD 15,000,000) after the conversion of the first EUR 3,000,000 of the Convertible Loans advanced to the Company prior to
September 4, 2014 into new preferred shares series C less the amount of all damages arising as a result of all breaches of the representations and warranties; provided, however, that the Reduced Valuation in no event shall be less than
EUR 6,000,000 (equaling USD 8,040,000). Each of the Shareholders undertakes individually for himself vis-à-vis each Holder of Preferred Shares Series C, to do or cause to be done everything necessary to implement the Compensatory
Share Capital Increase. Thus, the Shareholders undertake in particular to co-operate in the Compensatory Share Capital Increase as described by exercising their voting rights in the shareholders’ meetings of the Company and in the special
resolutions of the different classes of shares accordingly, and to waive the subscription rights to which they are entitled for the subscription to new shares to the extent described. Stephen Yoder shall be obliged to pay to the Holders of Preferred
Shares Series C in cash an amount equal to the portion of the Company’s share capital attributable to one share required for the Holders of Preferred Shares Series C to pay the total issue price of the additional shares issued in the
Compensatory Share Capital Increase; provided, however, that this liability shall, except in case of an intentional breach of the representations and warranties, be limited to EUR 25,000, among the Holders of Preferred Shares Series C pro rata
to the number of preferred shares series C held by them, respectively. If the Parties cannot agree on the Reduced Valuation within two calendar weeks after any of the Holders of Preferred Shares Series C has demanded a Compensatory Share Capital
Increase, then the Reduced Valuation shall be determined by an independent auditor to be appointed as arbitration expert (Schiedsgutachter) by the Shareholders with a simple majority of capital of all shares in the Company and a simple
majority of capital of all preferred shares series C. If the Shareholders have not so appointed an arbitration expert within two weeks after the request of any Shareholder to do so, the arbitration expert shall be appointed by the Industrie- und
Handelskammer für München und Oberbayern. The determination by the arbitration expert shall be final and binding on all Parties. The costs of the arbitration expert and the Industrie- und Handelskammer für München und Oberbayern,
if any, shall be borne by the Parties applying §§ 91 et seq. ZPO (German Code of Civil Procedure) mutatis mutandis. 

  

	4.	Claims for damages under this Sec. 5 may only be brought, if the aggregate loss arising as a result of all breaches of the representations and warranties exceeds the amount of EUR 100,000; if this limit is
exceeded, then the entire loss arising (and not only the excess) shall be replaced in accordance with Sec. 5 para. 3 above. 

  
 - 17 / 35 - 

	5.	All claims to which the Holders of Preferred Shares Series C may be entitled under this Sec. 5 shall be barred under the statute of limitations (verjähren) after September 1, 2016; provided,
however, that claims which relate to representations and warranties in connection with public law charges (taxes, customs, duties, social security contributions) in the business operations of the Company (including the representation and warranty
that sufficient reserves have been created for such risks), shall be barred under the statute of limitations six months after the respective notice of assessment of the tax authority or the social security institution fixing an additional public law
charge becomes binding (formelle und materielle Bestandskraft). The statute of limitations is interrupted in respect of an alleged misrepresentation or breach of warranties at the time of the receipt of a written instrument describing in
reasonable detail the facts on which such alleged misrepresentation or breach is based by Stephen Yoder. The statute of limitations under this para. 5 shall not apply to claims based on willful misconduct (Vorsatz). 

 

	6.	The claims of the Holders of Preferred Shares Series C under this Sec. 5 shall be the exclusive remedy of the Holders of Preferred Shares Series C for any breach of the representations and warranties included in
Exhibit 5.1 to this Investment Agreement and override any claims of the Holders of Preferred Shares Series C based on any other legal basis relating to representations and warranties, including, but not limited to (i) claims
pursuant to § 433 para. 1 sentence 2, § 434 et seq. BGB, § 311 para. 2 No. 1, §§ 275 et seq. and § 280 BGB, and (ii) the right to terminate, cancel, rescind
(zurücktreten) and/or void (anfechten) this Investment Agreement, in particular for any incorrectness or incompleteness of the representations and warranties or based upon them or for defects in substance or in title or for breach
of contractual or pre-contractual protection duties (Schutzpflichten). All such other rights shall be excluded, provided that remedies to which any Party may be entitled to with respect to any willful or deliberate (vorsätzlich)
material breach of this Investment Agreement shall remain unaffected. 

 Sec. 6 

Transaction Costs 
  

	1.	Each of the Parties shall bear its own legal and other costs and expenses in connection with the 2014 Financing Round, provided that the Company shall also bear the following external costs and expenses in connection
with the 2014 Financing Round as costs for the provision of further capital: 

  

	 	a.	The reasonable external legal and other costs and expenses of OrbiMed Private Investments III, LP and OrbiMed Associates III, LP (jointly “OrbiMed”) in connection with the 2014 Financing Round up to a
maximum amount of EUR 50,000 plus VAT (if any) upon presentation of corresponding invoices; 

  
 - 18 / 35 - 

	 	b.	The legal fees of Orrick, Herrington & Sutcliffe LLP in connection with the 2014 Financing Round; and 

  

	 	c.	Notary and court costs and similar expenses associated with the consummation of the 2014 Financing Round as well as all transaction taxes, if any. 

 

	2.	All payments pursuant to this Sec. 6 shall be made within two weeks after invoicing. OrbiMed shall be entitled to reimbursement of costs and expenses to the extent that these costs and expenses shall be borne by the
Company pursuant to para. 1 above and shall be entitled to deduct such amounts from the further payments into the capital reserves of the Company under Sec. 3 para. 1 a. and b. above. Irrespective of such deduction, any amounts deducted
from the further payments into the capital reserves of the Company under the preceding sentence shall be treated as fully rendered by OrbiMed to the Company for all purposes of this Investment Agreement and the CSA 2014. 

Sec. 7 
 Final Provisions

  

	1.	Each of the Investors shall be entitled to transfer its rights and obligations under this Investment Agreement together with the shares to which such rights and obligations relate in whole or in part to other Investors
or to other companies, provided that these companies in each case are affiliated with the transferring Investor within the meaning of § 15 AktG. In addition, each of the Investors shall be entitled to transfer its rights and obligations
under this Investment Agreement together with the shares to which such rights and obligations relate in whole or in part to other investment companies or equity funds whose business is managed or which are advised by the transferring Investor, a
company affiliated with the transferring Investor within the meaning of § 15 AktG, a general partner or a management company of the transferring Investor. This para. 1 shall not apply to the transfer to a portfolio company of the
respective Investor. 

  

	2.	Each of the Shareholders undertakes individually for himself vis-à-vis each other Shareholder, to impose on his individual legal successors, if any, the rights and obligations arising under this Investment
Agreement in such a way, that his individual legal successors are bound by the rights and obligations under this Investment Agreement as if they had themselves undertaken these rights and obligations. This shall also apply to the obligation
undertaken in this para. 2 to impose the rights and obligations under this Investment Agreement on any individual legal successors. 

  
 - 19 / 35 - 

	3.	The Investors, Shareholders or Subsequent Investors, respectively, are entitled to the rights attributed to the Investors, Shareholders or Subsequent Investors, as applicable, under this Investment Agreement to the
exclusion of any joint entitlement, i.e. in such a way that each of the Investors, Shareholders or Subsequent Investors, respectively, may each individually exercise the rights to which they are entitled, unless otherwise expressly provided. Joint
and several liability (gesamtschuldnerische Haftung) of the Investors, Shareholders or Subsequent Investors, respectively, shall be excluded, in particular without limitation for the total issue price of the new preferred shares series C
under Secs. 1 and 2 above and the further payments and contributions into the capital reserves of the Company under Sec. 3 above. 

  

	4.	Amendments and additions to this Investment Agreement must be made in writing to be effective, to the extent that notarization is not required. This shall also apply to a waiver of the written form requirement.

  

	5.	Should individual terms of this Investment Agreement be or become invalid or unenforceable or if this Investment Agreement contains gaps, this shall not affect the validity of the remaining terms of this Investment
Agreement or the CSA 2014. In place of the invalid, unenforceable or missing term, such valid term which the Parties would reasonably have agreed, had they been aware at the conclusion of this Investment Agreement that the relevant term was invalid,
unenforceable or missing, shall be deemed to have been agreed. Should a term of this Investment Agreement be or become invalid because of the scope or time of performance for which it provides, then the agreed scope or time of performance shall be
amended to correspond with the extent legally permitted. The Parties are aware of the German Federal Supreme Court’s (Bundesgerichtshof) case-law, whereby a severability clause merely reverses the burden of proof. However, it is the
Parties’ express intention to maintain the validity of the remaining provisions at all events and thus to exclude the applicability of § 139 German Civil Code (BGB) as a whole. 

 

	6.	Prior to any announcement, the Company and the Investors shall agree upon the form and contents of any press release with respect to the 2014 Financing Round. 

 

	7.	This Investment Agreement is governed by and shall be construed in accordance with the laws of the Federal Republic of Germany, without regard to its provisions of private international law and excluding the UN Sales
Convention (CISG). 

  
 - 20 / 35 - 

	8.	To the extent legally permissible, place of venue and performance shall be Munich, Germany. All disputes arising out of or in connection with this Investment Agreement shall be finally settled in accordance with the
Arbitration Rules of the German Institution of Arbitration e.V. (DIS) without recourse to the ordinary courts of law and according to the Arbitration Agreement enclosed as Exhibit 7.8. This shall include disputes regarding the validity,
the performance or the termination of this Investment Agreement in whole or in part including possible amendments of the same. The place of arbitration is Munich, Germany. The arbitration tribunal consists of three arbitrators. The language of the
arbitration proceedings is English. 

  

	9.	The Exhibits to this Investment Agreement are an essential part of it. The headings in this Investment Agreement only serve for a better orientation and are of no significance for the contents and interpretation of this
Investment Agreement. Explanations in a provision or Exhibit to this Investment Agreement are also deemed to be listed for purposes of all other provisions or Exhibits. 

 

	10.	German definitions in this document shall take precedence over the respective English terms. 

 Munich,
October 10, 2014 
  

					
	 /s/ i.V. Th.
Strassner            /s/ Hans Küpper
	 		 	 /s/ i.V. Th. Strassner

	 Pieris AG

(represented by the management board and the supervisory board)
	 		 	Prof. Skerra Beteiligungsgesellschaft mbH
			
	 /s/ i.V. Th. Strassner
	 		 	 /s/ i.V. Th. Strassner

	Dr. Steffen Schlehuber	 		 	Claus Schalper
			
	 /s/ i.V. Th. Strassner
	 		 	 /s/ i.V. Th. Strassner

	Dr. Karsten Schürrle	 		 	MAPO Beteiligungsgesellschaft mbH
			
	 /s/ i.V. Th. Strassner
	 		 	 /s/ i.V. Th. Strassner

	BioM Aktiengesellschaft Munich BioTech Development	 		 	BioM Venture Capital GmbH & Co. Fonds KG

  
 - 21 / 35 - 

					
			
	 /s/ i.V. Th. Strassner
	 		 	 /s/ i.V. Th. Strassner

	TransConnect Unternehmensberatungs- und Beteiligungs AG	 		 	The Global Life Science Ventures Fonds II GmbH & Co. KG
			
	 /s/ i.V. Th. Strassner
	 		 	 /s/ i.V. Th. Strassner

	The Global Life Science Ventures Fund II Limited Partnership	 		 	Gilde Europe Food & Agribusiness Fund B.V.
			
	 /s/ i.V. Th. Strassner
	 		 	 /s/ i.V. Th. Strassner

	BayTech Venture Capital GmbH & Co. KG	 		 	Coöperatieve AAC LS U.A.
			
	 /s/ Jiang Bian
	 		 	 /s/ i.V. Th. Strassner

	KfW	 		 	Technologie Beteiligungsfonds Bayern II GmbH & Co. KG
			
	 /s/ i.V. Th. Strassner
	 		 	 /s/ i.V. Th. Strassner

	OrbiMed Private Investments III, LP	 		 	OrbiMed Associates III, LP
			
	 /s/ i.V. Th. Strassner
	 		 	 /s/ i.V. Th. Strassner

	Novo Nordisk A/S	 		 	Cadila Healthcare Ltd.

  
 - 22 / 35 - 

 Table of Exhibits to the Investment Agreement 

 

			
	Exhibit A	  	Existing Shareholders
		
	Exhibit B	  	Investors / Holders of Preferred Shares Series C
		
	Exhibit C	  	CSA 2014
		
	Exhibit 1.1	  	Restated Articles of Association
		
	Exhibit 2.3-1	  	Joinder of Subsequent Investor to the Investment Agreement and the CSA 2014
		
	Exhibit 2.3-2	  	Joinder of Subsequent Investor to the Arbitration Agreement
		
	Exhibit 2.3-3	  	Subscription Declaration
		
	Exhibit 5.1	  	Representations and Warranties
		
	Exhibit 7.8	  	Arbitration Agreement

 Exhibits to Representations and Warranties 

 

			
	Exhibit 5.1.B.1	  	Audited financial statements as of December 31, 2013
		
	Exhibit 5.1.B.2	  	Unaudited interim statements as of August 31, 2014
		
	Exhibit 5.1.D.2	  	Litigation
		
	Exhibit 5.1.D.3	  	IP
		
	Exhibit 5.1.D.4	  	Material Contracts
		
	Exhibit 5.1.E	  	Employees

  
 - 23 / 35 - 

 Exhibit A 
  

	1.	Prof. Skerra Beteiligungsgesellschaft mbH, Max-Lehner-Straße 19, 85354 Freising, Germany 

  

	2.	Dr. Steffen Schlehuber, In den Kappesgärten 22, 67152 Ruppertsberg, Germany 

  

	3.	Claus Schalper, Kaiser-Ludwig-Platz 1, 80336 Munich, Germany 

  

	4.	Dr. Karsten Schürrle, Palmstraße 7, 60316 Frankfurt a.M., Germany 

  

	5.	MAPO Beteiligungsgesellschaft mbH, Hubertusweg 34, 85540 Haar, Germany 

  

	6.	BioM Aktiengesellschaft Munich BioTech Development, Am Klopferspitz 19 a, 82152 Planegg-Martinsried, Germany 

  

	7.	BioM Venture Capital GmbH & Co. Fonds KG, Am Klopferspitz 19 a, 82152 Planegg-Martinsried, Germany 

  

	8.	TransConnect Unternehmensberatungs- und Beteiligungs AG, Prinzregentenstraße 56, 80538 Munich, Germany 

  

	9.	The Global Life Science Ventures Fonds II GmbH & Co. KG, Von-der-Tann-Straße 3, 80539 Munich, Germany 

  

	10.	The Global Life Science Ventures Fund II Limited Partnership, PO Box 431, Alexander House,13-15 Victoria Road, St. Peter Port, Guernsey, G41 3ZD 

 

	11.	Gilde Europe Food & Agribusiness Fund B.V., Newtonlaan 91, 3584 BP Utrecht, The Netherlands 

  

	12.	Coöperatieve AAC LS U.A., Gooimeer 2-35, P.O. Box 5187, 1410 AD Naarden, The Netherlands 

  

	13.	BayTech Venture Capital GmbH & Co. KG, Herzog-Heinrich-Straße 22, D-80336 Munich, Germany 

  

	14.	KfW, Ludwig-Erhard-Platz 1-3, 53179 Bonn, Germany 

  

	15.	Technologie Beteiligungsfonds Bayern II GmbH & Co. KG, Ländgasse 135a, 84028 Landshut, Germany 

  

	16.	OrbiMed Private Investments III, LP, 601 Lexington Avenue, 54th Floor, New York, NY 10022, USA; 

 

	17.	OrbiMed Associates III, LP, 601 Lexington Avenue, 54th Floor, New York, NY 10022, USA; 

 

	18.	Novo Nordisk A/S, Novo Allé, 2880 Bagsværd, Denmark. 

  
 - 24 / 35 - 

 Exhibit B 
  

	1.	OrbiMed Private Investments III, LP, 601 Lexington Avenue, 54th Floor, New York, NY 10022, USA 

 

	2.	OrbiMed Associates III, LP, 601 Lexington Avenue, 54th Floor, New York, NY 10022, USA 

 

	3.	Cadila Healthcare Ltd., Zydus Tower, Satellite Cross Roads, Ahmedabad - 380 015, India 

  

	4.	Novo Nordisk A/S, Novo Allé, 2880 Bagsværd, Denmark 

  

	5.	TransConnect Unternehmensberatungs- und Beteiligungs AG, Prinzregentenstraße 56, 80538 Munich, Germany 

  

	6.	BioM Aktiengesellschaft Munich BioTech Development, Am Klopferspitz 19 a, 82152 Planegg-Martinsried, Germany 

  

	7.	The Global Life Science Ventures Fonds II GmbH & Co. KG, Von-der-Tann-Straße 3, 80539 Munich, Germany 

  

	8.	The Global Life Science Ventures Fund II Limited Partnership, PO Box 431, Alexander House,13-15 Victoria Road, St. Peter Port, Guernsey, G41 3ZD 

 

	9.	Gilde Europe Food & Agribusiness Fund B.V., Newtonlaan 91, 3584 BP Utrecht, The Netherlands 

  

	10.	BayTech Venture Capital GmbH & Co. KG, Herzog-Heinrich-Straße 22, D-80336 Munich, Germany 

  

	11.	Coöperatieve AAC LS U.A., Gooimeer 2-35, P.O. Box 5187, 1410 AD Naarden, The Netherlands 

  
 - 25 / 35 - 

 Exhibit C 

  
 - 26 / 35 - 

 Exhibit 1.1 

  
 - 27 / 35 - 

 Exhibit 2.3-1 

Joinder
 to the 

Pieris AG 
 INVESTMENT
AGREEMENT and CSA 2014 
 dated              2014 

On October 10, 2014, Pieris AG (“Company”) closed the 2014 Financing Round. To this end, the shareholders of the Company, the Company
and further parties have entered into an investment agreement Pieris AG, Freising, Germany dated October 10, 2014 (“Investment Agreement”) and a consolidated shareholders’ agreement 2014 Pieris AG, Freising, Germany dated
October 10, 2014 (“CSA 2014”). Capitalized terms used but not defined herein shall have the same meaning as given to them in any definitions in the Investment Agreement and/or the CSA 2014. 

Pursuant to Sec. 2 of the Investment Agreement, the undersigned 
  

 
  

 
  

 
 [insert name and
address of Subsequent Investor] 
 hereby becomes a party to the Investment Agreement and the CSA 2014 with the rights and duties of a Subsequent Investor,
an Investor, a Holder of Preferred Shares Series C, a Preferred Shareholder, a Shareholder and a Party. To the extent that the Investment Agreement and/or the CSA 2014 refer to “Subsequent Investor(s)” and / or “Investor(s)” and
/ or “Holder(s) of Preferred Shares Series C” and / or “Preferred Shareholder(s)” and / or “Shareholder(s)” and / or “Party” / “Parties”, this shall encompass
                     [insert name of Subsequent Investor] as well. 

The total investment of                      [insert name
of Subsequent Investor] under the Investment Agreement amounts to 
 EUR         . 

  
 - 28 / 35 - 

 Thus,
                     [insert name of Subsequent Investor] will subscribe and take over
                 new preferred shares series C in registered form under Sec. 2 of the Investment Agreement for the amount of EUR 1.00 per new preferred share
series C, and moreover render further payments into the capital reserves of the Company pursuant to § 272 para. 2 No. 4 HGB in cash in the amount of EUR 5.0373 (equaling approx. USD 6.75) per new preferred share
series C pursuant to Sec. 3 paras. 5 and 6 of the Investment Agreement. 
  

	
	                     [place],
                     [date]
	
	  

	([insert name of Subsequent Investor])

  
 - 29 / 35 - 

 Exhibit 2.3-2 

Joinder
 to the 

Pieris AG 
 ARBITRATION
AGREEMENT 
 dated              2014 

On October 10, 2014, Pieris AG (“Company”) closed the 2014 Financing Round. To this end, the shareholders of the Company, the Company
and further parties have entered into an investment agreement Pieris AG, Freising, Germany dated October 10, 2014 (“Investment Agreement”), a consolidated shareholders’ agreement 2014 Pieris AG, Freising, Germany dated
October 10, 2014 (“CSA 2014”) and an arbitration agreement of even date (“Arbitration Agreement”). Capitalized terms used but not defined herein shall have the same meaning as given to them in any definitions
in the Investment Agreement and/or the CSA 2014 and/or the Arbitration Agreement. 
 On the day hereof, the undersigned 

 
  

 
  

 
  

[insert name and address of Subsequent Investor] 

joined and became a party to the Investment Agreement and the CSA 2014 by submission of a separate joinder commitment with the rights and duties of a
Subsequent Investor, an Investor, a Holder of Preferred Shares Series C, a Preferred Shareholder, a Shareholder and a Party. 
 The undersigned 

 
  

 
  

 
  

[insert name and address of Subsequent Investor] 

  
 - 30 / 35 - 

 hereby becomes also a party to the Arbitration Agreement. 

Thus, place of venue and performance with regard to all disputes arising out of the Investment Agreement and the CSA 2014 shall, to the extent legally
permissible, be Munich, Germany. All disputes arising out of or in connection with the Investment Agreement and/or the CSA 2014 shall be finally settled in accordance with the Arbitration Rules of the German Institution of Arbitration e.V. (DIS)
without recourse to the ordinary courts of law. This shall include disputes regarding the validity, the performance or the termination of the Investment Agreement and/or the CSA 2014 in whole or in part including possible amendments of the same. The
place of arbitration is Munich, Germany. The arbitration tribunal consists of three arbitrators. The language of the arbitration proceedings is English. 
  

	
	                     [place],
                     [date]
	
	  

	([insert name of Subsequent Investor])

  
 - 31 / 35 - 

 Exhibit 2.3-3 

Declaration to Subscribe for Further New Shares (2nd Tranche) 

of 
 Pieris AG 

On October 10, 2014, Pieris AG (“Company”) closed the 2014 Financing Round, and the shareholders of the Company, the Company and further
parties have entered into an investment agreement Pieris AG, Freising, Germany dated October 10, 2014 (“Investment Agreement”) and a consolidated shareholders’ agreement 2014 Pieris AG, Freising, Germany dated
October 10, 2014 (“CSA 2014”). Capitalized terms used but not defined herein shall have the same meaning as given to them in any definitions in the Investment Agreement and/or the CSA 2014. 

Pursuant to Sec. 2 of the Investment Agreement, the undersigned 
  

 
  

 
  

 
 [insert name and
address of Investor] 
 hereby agrees to invest in the course of the Second Tranche under the Investment Agreement a further amount of 

EUR         . 

Thus,                      [insert name of Investor] will
subscribe and take over                      further new preferred shares series C in registered form under Sec. 2 of the Investment Agreement for
the amount of EUR 1.00 per new preferred share series C, and moreover render further payments into the capital reserves of the Company pursuant to § 272 para. 2 No. 4 HGB in cash in the amount of EUR 5.0373
(equaling approx. USD 6.75) per new preferred share series C subscribed under Sec. 2 of the Investment Agreement pursuant to Sec. 3 paras. 5 and 6 of the Investment Agreement. 

 

	
	                     [place],
                     [date]
	
	  

	([insert name of Investor])

  
 - 32 / 35 - 

 Exhibit 5.1 

  
 - 33 / 35 - 

 Exhibit 7.8 

Arbitration Agreement 
 With regard to all
disputes arising out of the Investment Agreement and the Consolidated Shareholders’ Agreement 2014 both dated October 10, 2014 of Pieris AG, Lise-Meitner-Straße 30, 85354 Freising, Germany, the Parties agree on the following
arbitration clause: 
 Place of venue and performance shall, to the extent legally permissible, be Munich, Germany. All disputes arising out of or in
connection with the Investment Agreement and/or the Consolidated Shareholders’ Agreement 2014 shall be finally settled in accordance with the Arbitration Rules of the German Institution of Arbitration e.V. (DIS) without recourse to the ordinary
courts of law. This shall include disputes regarding the validity, the performance or the termination of the Investment Agreement and/or the Consolidated Shareholders’ Agreement 2014 in whole or in part including possible amendments of the
same. The place of arbitration is Munich, Germany. The arbitration tribunal consists of three arbitrators. The language of the arbitration proceedings is English. 

Munich, October 10, 2014 
  

					
	 /s/ Hans
Küpper            /s/ i.V. Th. Strassner
	 		 	 /s/ i.V. Th. Strassner

	 Pieris AG

(represented by the management board and the supervisory board)
	 		 	Prof. Skerra Beteiligungsgesellschaft mbH
			
	 /s/ i.V. Th. Strassner
	 		 	 /s/ i.V. Th. Strassner

	Dr. Steffen Schlehuber	 		 	Claus Schalper
			
	 /s/ i.V. Th. Strassner
	 		 	 /s/ i.V. Th. Strassner

	Dr. Karsten Schürrle	 		 	MAPO Beteiligungsgesellschaft mbH
			
	 /s/ i.V. Th. Strassner
	 		 	 /s/ i.V. Th. Strassner

	BioM Aktiengesellschaft Munich BioTech Development	 		 	BioM Venture Capital GmbH & Co. Fonds KG

  
 - 34 / 35 - 

					
			
	 /s/ i.V. Th. Strassner
	 		 	 /s/ i.V. Th. Strassner

	TransConnect Unternehmensberatungs- und Beteiligungs AG	 		 	The Global Life Science Ventures Fonds II GmbH & Co. KG
			
	 /s/ i.V. Th. Strassner
	 		 	 /s/ i.V. Th. Strassner

	The Global Life Science Ventures Fund II Limited Partnership	 		 	Gilde Europe Food & Agribusiness Fund B.V.
			
	 /s/ i.V. Th. Strassner
	 		 	 /s/ i.V. Th. Strassner

	BayTech Venture Capital GmbH & Co. KG	 		 	Coöperatieve AAC LS U.A.
			
	 /s/ i.V. Th. Strassner
	 		 	 /s/ i.V. Th. Strassner

	KfW	 		 	Technologie Beteiligungsfonds Bayern II GmbH & Co. KG
			
	 /s/ i.V. Th. Strassner
	 		 	 /s/ i.V. Th. Strassner

	OrbiMed Private Investments III, LP	 		 	OrbiMed Associates III, LP
			
	 /s/ i.V. Th. Strassner
	 		 	 /s/ i.V. Th. Strassner

	Novo Nordisk A/S	 		 	Cadila Healthcare Ltd.

  
 - 35 / 35 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}]]